WO2022035904A1 - Proteasome enhancers and uses thereof - Google Patents

Proteasome enhancers and uses thereof Download PDF

Info

Publication number
WO2022035904A1
WO2022035904A1 PCT/US2021/045448 US2021045448W WO2022035904A1 WO 2022035904 A1 WO2022035904 A1 WO 2022035904A1 US 2021045448 W US2021045448 W US 2021045448W WO 2022035904 A1 WO2022035904 A1 WO 2022035904A1
Authority
WO
WIPO (PCT)
Prior art keywords
aryl
alkyl
heterocyclyl
compound
acyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2021/045448
Other languages
English (en)
French (fr)
Inventor
Jetze J. Tepe
Sophia STAERZ
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Michigan State University
Original Assignee
Michigan State University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Michigan State University filed Critical Michigan State University
Priority to PCT/US2021/045448 priority Critical patent/WO2022035904A1/en
Priority to AU2021324687A priority patent/AU2021324687A1/en
Priority to JP2023509838A priority patent/JP2023538325A/ja
Priority to EP21856603.2A priority patent/EP4196464A4/en
Priority to US18/041,193 priority patent/US20240043394A1/en
Priority to MX2023001761A priority patent/MX2023001761A/es
Priority to CA3191312A priority patent/CA3191312A1/en
Publication of WO2022035904A1 publication Critical patent/WO2022035904A1/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D279/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom and one sulfur atom as the only ring hetero atoms
    • C07D279/10—1,4-Thiazines; Hydrogenated 1,4-thiazines
    • C07D279/14—1,4-Thiazines; Hydrogenated 1,4-thiazines condensed with carbocyclic rings or ring systems
    • C07D279/18—[b, e]-condensed with two six-membered rings
    • C07D279/22—[b, e]-condensed with two six-membered rings with carbon atoms directly attached to the ring nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D279/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom and one sulfur atom as the only ring hetero atoms
    • C07D279/10—1,4-Thiazines; Hydrogenated 1,4-thiazines
    • C07D279/14—1,4-Thiazines; Hydrogenated 1,4-thiazines condensed with carbocyclic rings or ring systems
    • C07D279/18—[b, e]-condensed with two six-membered rings
    • C07D279/22—[b, e]-condensed with two six-membered rings with carbon atoms directly attached to the ring nitrogen atom
    • C07D279/24—[b, e]-condensed with two six-membered rings with carbon atoms directly attached to the ring nitrogen atom with hydrocarbon radicals, substituted by amino radicals, attached to the ring nitrogen atom
    • C07D279/28—[b, e]-condensed with two six-membered rings with carbon atoms directly attached to the ring nitrogen atom with hydrocarbon radicals, substituted by amino radicals, attached to the ring nitrogen atom with other substituents attached to the ring system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/5415—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with carbocyclic ring systems, e.g. phenothiazine, chlorpromazine, piroxicam
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/30—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
    • C07D207/32—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C07D207/325—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms with substituted hydrocarbon radicals directly attached to the ring nitrogen atom
    • C07D207/327—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/08—Indoles; Hydrogenated indoles with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, directly attached to carbon atoms of the hetero ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/30—Indoles; Hydrogenated indoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to carbon atoms of the hetero ring
    • C07D209/32—Oxygen atoms
    • C07D209/34—Oxygen atoms in position 2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/56—Ring systems containing three or more rings
    • C07D209/80—[b, c]- or [b, d]-condensed
    • C07D209/82—Carbazoles; Hydrogenated carbazoles
    • C07D209/86—Carbazoles; Hydrogenated carbazoles with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to carbon atoms of the ring system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/56—Ring systems containing three or more rings
    • C07D209/80—[b, c]- or [b, d]-condensed
    • C07D209/82—Carbazoles; Hydrogenated carbazoles
    • C07D209/88—Carbazoles; Hydrogenated carbazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the ring system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/64—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms, e.g. histidine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
    • C07D235/06—Benzimidazoles; Hydrogenated benzimidazoles with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
    • C07D235/24—Benzimidazoles; Hydrogenated benzimidazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
    • C07D235/26—Oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D265/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom and one oxygen atom as the only ring hetero atoms
    • C07D265/28—1,4-Oxazines; Hydrogenated 1,4-oxazines
    • C07D265/34—1,4-Oxazines; Hydrogenated 1,4-oxazines condensed with carbocyclic rings
    • C07D265/36—1,4-Oxazines; Hydrogenated 1,4-oxazines condensed with carbocyclic rings condensed with one six-membered ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D265/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom and one oxygen atom as the only ring hetero atoms
    • C07D265/28—1,4-Oxazines; Hydrogenated 1,4-oxazines
    • C07D265/34—1,4-Oxazines; Hydrogenated 1,4-oxazines condensed with carbocyclic rings
    • C07D265/38—[b, e]-condensed with two six-membered rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D279/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom and one sulfur atom as the only ring hetero atoms
    • C07D279/10—1,4-Thiazines; Hydrogenated 1,4-thiazines
    • C07D279/14—1,4-Thiazines; Hydrogenated 1,4-thiazines condensed with carbocyclic rings or ring systems
    • C07D279/16—1,4-Thiazines; Hydrogenated 1,4-thiazines condensed with carbocyclic rings or ring systems condensed with one six-membered ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/16—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms
    • C07D295/18—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms by radicals derived from carboxylic acids, or sulfur or nitrogen analogues thereof
    • C07D295/182—Radicals derived from carboxylic acids
    • C07D295/192—Radicals derived from carboxylic acids from aromatic carboxylic acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/40—Heterocyclic compounds containing purine ring systems with halogen atoms or perhalogeno-alkyl radicals directly attached in position 2 or 6
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems

Definitions

  • proteostasls The regulation of protein synthesis, degradation, folding, trafficking and aggregation within a cell are collectively known as proteostasls.
  • proteostasis is maintained by a wide array of cellular machinery that work to ensure that proteins are present in the proper location, amounts and form to perform their respective functions.
  • proteostasis becomes dysregulated there can be disastrous effects on the cell and even on neighboring cells.
  • neurodegenerative diseases such as Parkinson’s disease (PD), Alzheimer’s disease (AD), Huntington’s disease (HD) and amyotrophic lateral sclerosis (ALS).
  • IDPs intrinsically disordered proteins
  • aggregation and oligomerization are used interchangeably.
  • IDPs IDP ⁇ -synuclein
  • a-syn the IDP ⁇ -synuclein
  • IDPs are named for their iack of tertiary structure allowing them to adopt numerous conformations and interact with multiple binding partners. IDPs are generally short-lived signaling proteins or transcription factors that are highly bound to other cellular components keeping free cytosolic levels low.
  • IDPs are readily degraded by the 20S proteasome, the default protease responsible for IDP digestion.
  • the accumulation of IDPs seen in neurodegenerative diseases can begin as a result of one of several disruptions (e.g. mutations, changes in expression, oxidative stress, aging, proteasome impairment, etc.) to their normal regulation. While a-syn may not be the sole cause of PD, there is strong evidence supporting its key role in the disease, including familial forms of PD resulting from mutations in the SNCA gene. Elevated monomeric a-syn levels are aiso known to cause apoptosis-inducing aggregation in neurons.
  • oligomeric forms of a-syn and other IDPs have recently been shown to directly inhibit the proteasome, further disrupting its ability to regulate IDPs concentrations. These data collectively suggest that the accumulation of a-syn and formation of oligomeric species of the !DP play a critical role in the progression of PD. Due to a lack of defined binding pockets, IDPs such as a-syn, and their aggregation are difficult to target through traditional small molecule drug design. There are currently no effective treatments to hinder the progression of neurodegenerative diseases that are associated with IDP accumulation.
  • FIGS. 2A-2F are cartoons of preferred docking site of GPZ analogs, utilizing Autodock Vina and PyMol, in the a1 -2 intersubunit pocket of the 20S proteasome (FIG. 2A); a cartoon of the location of two amino acid residues of interest, Y159 and C161 (FIG. 2B); and cartoons of predicted binding interaction of compound 2 (FIG. 2C), compound 7 (FIG. 2D), compound 9 (FIG. 2E), and compound 19 (FIG. 2F), viewed using BIOVIA Discovery Studio 2020.
  • FIGS. 4A-4B show representative Western blot (1 of 4) of A53T a- synuclein in Hek-293T cells treated with vehicle (DMSO), BTZ, TCH-165, compound 19, compound 2 or inactive control 8 (FIG. 4A); and quantitation of A53T a-syn remaining (using A53T a-syn/p-actin ratio of 4 separate experiments) for treatments normalized to vehicle control (100%). Error bars denote standard deviation.
  • the disclosure relates to small molecules that enhance proteasome function and restore the activity of impaired proteasomes.
  • Small molecule proteasome enhancers prevent the toxic accumulation of aggregation- prone proteins and prevent neuronal ceil death caused by aggregation-prone proteins.
  • the disclosure therefore relates to the use of small molecules as therapeutic agents to treat neurodegenerative diseases.
  • Neurodegenerative diseases include, but are not limited to Alzheimer's disease (AD) and other dementias, Parkinson's disease (PD) and PD-related disorders, Prion disease, Motor neuron diseases (MND), Huntington’s disease (HD), Spinocerebellar ataxia (SCA), Spina! muscular atrophy (SMA).
  • the disclosure relates to a chemotype that has been shown herein to be a biologically active enhancers of mammalian proteasomes.
  • the chemotype described herein is based on chlorpromazine and derivatives thereof.
  • the disclosure relates to chlorpromazine and derivates thereof, and their use to, among other things, prevent or slow down the progression of neurodegenerative diseases.
  • the disclosure therefore relates to compounds of the formula (I): I or a pharmaceutically acceptable salt, polymorph, prodrug, solvate or clathrate thereof, wherein:
  • R' is hydrogen, alkyl, cycloalkyl, aryi, heterocyclyl or heteroaryl
  • R 2 is hydrogen, alkyl, cycloalkyl, aryi, heterocyclyl or heteroaryl;
  • R 3 is aryl or heteroaryl (e.g., tricyclic heteroaryl, such as phenothiazine and carbazole; and bicyclic heteroaryl, such as indole);
  • X 1 is N or CR 5 , wherein R 5 is absent (e.g., when X 1 is alkenyl), hydrogen, alkyl, heterocyclyl or aryl; X 2 is alkyl or alkenyl;
  • X 3 is alkyl or alkenyl; g is 0 or 1 ; and t is 0 or 1 ; provided that g and t are not simultaneously 0. In some examples, g is 0 and t is 1 . In other examples, g is 1 and t is 0.
  • One example of a compound of the formula (I) is a compound of the formula (la): or a pharmaceutically acceptable salt, polymorph, prodrug, solvate or clathrate thereof, wherein:
  • R 1 is hydrogen, alkyl, cycloalkyi, aryl, heterocyciyl or heteroaryl;
  • R 2 is hydrogen, alkyl, cycloalkyi, aryl, heterocyciyl or heteroaryl;
  • R 3 is aryl or heteroaryl (e.g., tricyclic heteroaryl, such as phenothiazine and carbazole; and bicyclic heteroaryl, such as indole);
  • X 1 is N or CR 5 , wherein R 6 is absent (e.g., when X 1 is alkenyl), hydrogen, alkyl, heterocyciyl or aryl;
  • X 2 is alkyl or alkenyl
  • X 3 is alkyl or alkenyl; g is 0 or 1 ; and t is 0 or 1 ; provided that g and t are not simultaneously 0;
  • R 4 is alkyl, cycloalkyi, aryl, heteroaryl, halo, amino, OR 7 , wherein R 7 is hydrogen, alkyl, cycloalkyi, aryl or arylalkyl, S(O) X , wherein x is 0, 1 or 2, acyl, amido or heterocyciyl;
  • R 6 is alkyl, cycloalkyi, aryl, heteroaryl, halo, amino, OR 7 , wherein R 7 is hydrogen, alkyl, cycloalkyi, aryl or arylalkyl, S(O) X , wherein x is 0, 1 or 2, acyl, amido or heterocyciyl; p is 0, 1 , 2, 3 or 4; and s is 0, 1 , 2, 3 or 4.
  • R 7 is hydrogen, alkyl, cycloalkyi, aryl or arylalkyl, S(O) X , wherein x is 0, 1 or 2, acyl, amido or heterocyciyl; p is 0, 1 , 2, 3 or 4; and s is 0, 1 , 2, 3 or 4.
  • a compound of formula (I) is a compound of the formula (If): or a pharmaceutically acceptable salt, polymorph, prodrug, solvate or clathrate thereof, wherein:
  • R 3 is aryl or heteroaryl (e.g., tricyclic heteroaryl, such as phenothiazine and carbazole; and bicyclic heteroaryl, such as indole);
  • X 1 is N or CR°, wherein R ⁇ is absent (e.g., when X 1 is alkenyl), hydrogen, alkyl, heterocyciyl or aryl;
  • X 3 is alkyl or alkenyl
  • X 3 is alkyl or alkenyl; g is 0 or 1 ; and t is 0 or 1 ; provided that g and t are not simultaneously 0. In some examples, g is 0 and t is
  • g is 1 and t is 0.
  • One example of a compound of the formula (I) is a compound of or a pharmaceutically acceptable salt, polymorph, prodrug, solvate or clathrate thereof, wherein:
  • X 1 is N or CR 5 , wherein R 5 is absent (e.g., when X 1 is alkenyl), hydrogen, alkyl, heterocyciyl or aryl;
  • X 2 is alkyl or alkenyl
  • X 3 is alkyl or alkenyl; g is 0 or 1 ; and t is 0 or 1 ; provided that g and t are not simultaneously 0. In some examples, g is 0 and t is
  • g is 1 and t is 0.
  • a compound of formula (I) are compounds of the formulae (Ih) and (II): or a pharmaceutically acceptable salt, polymorph, prodrug, solvate or clathrate thereof, wherein: n is 0, 1 or 2.
  • n 0, 1 or 2;
  • Y is S(O)x, wherein x is 0, 1 or 2, O, CH?, or Y is N-R”, wherein R 1 ' is a carbon with at least one halo (e.g., one to three halo, such as CHF 2 , GCF 3 , CCI3), alkyl, aryl, acyl or heterocyclyl;
  • R 1 ' is a carbon with at least one halo (e.g., one to three halo, such as CHF 2 , GCF 3 , CCI3), alkyl, aryl, acyl or heterocyclyl;
  • R 7 , R 8 , R 9 , and R 10 are each independently halo, a carbon with at least one halo (e.g., one to three halo, such as CHF 2 , CCF 3 , CCI3), alkyl, aryl, acyl or heterocyclyl; p is 0, 1 , 2, 3 or 4; arid s is 0, 1 , 2, 3 or 4.
  • halo e.g., one to three halo, such as CHF 2 , CCF 3 , CCI3
  • p is 0, 1 , 2, 3 or 4
  • arid s is 0, 1 , 2, 3 or 4.
  • the alkyl, cycloalkyl, aryl, heterocyclyl, and heteroaryl groups of R 1 can be unsubstituted or substituted as described herein.
  • halo e.g., Cl, Br, and F
  • OR 12 wherein R 12 is hydrogen, aikyl, cycloalkyl, aryl or arylalkyl, S(O) X , wherein x is 0, 1 or 2, acyl, amido or heterocyclyl.
  • the alkyl, cycloalkyl, aryl, heterocyclyl, and heteroaryl groups of R 2 can be unsubstituted or substituted as described herein.
  • alkyl, cycloalkyl, aryl, heterocyclyl, or heteroaryl groups of R 2 when they are substituted, they can be substituted with halo (e.g., Cl, Br, and F), amino, OR 12 , wherein R 12 is hydrogen, aikyl, cycloalky I, aryl or arylalkyl, S(O) X , wherein x is 0, 1 or 2, acyl, amido or heterocyclyl.
  • halo e.g., Cl, Br, and F
  • R 12 is hydrogen, aikyl, cycloalky I, aryl or arylalkyl, S(O) X , wherein x is 0, 1 or 2, acyl, amido or heterocyclyl.
  • the aryl or heteroaryl groups of R 3 can be unsubstituted or substituted as described herein.
  • the aryl or heteroaryl groups of R 3 can be substituted with alkyl, cycloalkyl, aryl, heteroaryl, halo (e.g., Cl, Br, and F), amino, OR 12 , wherein R 12 is hydrogen, alkyl, cycloalkyl, aryl or arylalkyl, S(O) X , wherein x is 0, 1 or 2, acyl, amido or heterocyclyl.
  • An example of a compound of the formula (I) includes, but is not limited to, a compound of the formula: pharmaceutically acceptable salts, polymorphs, prodrugs, solvates or clathrates thereof.
  • n 0, 1 or 2;
  • R 7 and R 6 are each Independently halo, a carbon with at least one halo (e.g., one to three halo, such as CHF 2 , CCF 3 , CCb), alkyl, aryl, acyl or heterocyclyl; and R 13 is a heterocyclyl group of the formula: wherein W is N or C-R’ 4 ; X is N or C-R’ 4 ; Y is N or C-R’ 4 ; and Z is N or C-R 14 ; wherein R 14 is hydrogen, an electron withdrawing group, alkyl, cycloalkyl, aryl, heteroaryl, acyl, amido or heterocyclyl, wherein each aryl or heteroaryl is optionally substituted with halo, amino, OR 7 , wherein R 7 is hydrogen, alkyl, cycloalkyl, aryl or arylalkyl, S(O) X , wherein x is 0, 1 or 2, acyl, amido
  • R 4 is alkyl, cycloalkyl, aryl, heteroaryl, halo, amino, OR 7 , wherein R 7 is hydrogen, alkyl, cycloalkyl, aryl or arylalkyl, S(O) X , wherein x is 0, 1 or 2, acyl, amido or heterocyclyl; and p is 0, 1 , 2, 3 or 4; wherein the dashed line can represent a double bond;
  • A is S(O) X , wherein x is 0, 1 or 2; O; C(R’ 4 ) 2 , wherein each R i4 is independently hydrogen, an electron withdrawing group, alkyl, cycloalkyl, aryl, heteroaryl, acyl, amido or heterocyclyl, wherein each aryl or heteroaryl is optionally substituted with halo, amino, OR 7 , wherein R 7 is hydrogen, alkyl, cycloalkyl, aryl or arylalkyl, S(O) X , wherein x is 0, 1 or 2, acyl, amido or heterocyclyl; or A is N-R 1 ’ , wherein R 11 is a carbon with at least one halo (e.g., one to three halo, such as CHF : , alkyl, aryl, acyl or heterocyclyl; (C) wherein T is CR 14 , wherein each R 14 is independently hydrogen, an electron withdrawing group
  • B is C-R' 4 , wherein R 14 is hydrogen, an electron withdrawing group, alkyl, cycloalkyl, aryl, heteroaryl, acyl, amido or heterocyclyl, wherein each aryl or heteroaryl is optionally substituted with halo, amino, OR 7 , wherein R 7 is hydrogen, alkyl, cycloalkyl, aryl or arylalkyl, S(O) X , wherein x is 0, 1 or 2, acyl, amido or heterocyclyl; or B is N;
  • electron withdrawing group is any atom or group that draws electron density from neighboring atoms towards itself, e.g., by resonance or inductive effects.
  • Suitable electron withdrawing groups include, but are not limited to, halo, cyano, fluoroalkyl (e.g., CF 3 ), perfluoroalkyl, carboxy (CO2H), aminocarbonyl, alkoxycarbonyl, aryloxycarbonyl, halocarbonyl (e.g., CF 3 C(O)-), formyl (-C(O)H), acyl, S(O), SO 2 , alkoxysulfonyl (e.g., RSO2-), aryloxysulfonyl (e.g., aryl-O-SO 2 -), perfluoroalkylsulfonyl (e.g., CF3SO2-), aikylsulfonyl (e.g.
  • the compounds of the formula (III) when R 13 is a heterocyclyl of the formula (d), Y can be N. Alternatively, when R' 3 is a heterocyclyl of the formula (d), at least two of W, X, Y, and Z is N.
  • the compounds of the formula (III) can be compounds of the formulae: pharmaceutically acceptable salt, polymorph, prodrug, solvate or clathrate thereof.
  • R 13 when R 13 is a heterocyclyl of the formula (f), Y can be N.
  • R' 3 when R' 3 is a heterocyclyl of the formula (f), at least two of W, X, Y, and Z is N,
  • the compounds of the formula (III) can be compounds of the formulae: prodrug, solvate or clathrate thereof.
  • the disclosure also relates to compounds of the formula (IV): (IV) or a pharmaceutically acceptable salt, polymorph, prodrug, solvate or clathrate thereof, wherein: n is 0, 1 or 2; each G is independently alkyl (e.g., CH 2 ) or C(O);
  • X s is N or CR 5 , wherein R s is hydrogen, alkyl, heterocyclyl or aryl;
  • R 7 and R 6 are each independently halo, a carbon with at least one halo (e.g., one to three halo, such as CHF 2 , CCF3, CCb), alkyl, aryl, acyl or heterocyclyl; and R i3 is a heterocyclyl group of the formula: wherein W is N or C-R 14 ; X is N or C-R 14 ; Y is N or C-R 14 ; and Z is N or C-R 14 ; wherein R 14 is hydrogen, an electron withdrawing group, alkyl, cycloalkyl, aryl, heteroaryl, acyl, amido or heterocyclyl, wherein each aryl or heteroaryl is optionally substituted with halo, amino, OR 7 , wherein R 7 is hydrogen, alkyl, cycloalkyl, aryl or arylalkyi, S(O) X , wherein x is 0, 1 or 2, acyl, amido or heterocycly
  • R 4 is alkyi, cycloalkyl, aryl, heteroaryl, halo, amino, OR 7 , wherein R 7 is hydrogen, alkyl, cycloalkyi, aryl or arylalkyl, S(O) X , wherein x is 0, 1 or 2, acyl, amido or heterocyclyl; and p is 0, 1 , 2, 3 or 4; wherein A is S(O) X , wherein x is 0, 1 or 2; O; C-R 14 , wherein R 14 is hydrogen, alkyl, cycloalkyl, aryl, heteroaryl, acyl, amido or heterocyclyl, wherein each aryl or heteroaryl is optionally substituted with halo, amino, OR 7 , wherein R 7 is hydrogen, alkyl, cycloalkyl, aryl or arylalkyl, S(O) X , wherein x is 0, 1 or 2, acyl, amido or heterocyclyl
  • B is C-R 14 , wherein R 14 is hydrogen, an electron withdrawing group, alkyl, cycloalkyl, aryl, heteroaryl, acyl, amido or heterocyclyl, wherein each aryl or heteroaryl is optionally substituted with halo, amino, OR 7 , wherein R 7 is hydrogen, alkyl, cycloalkyl, aryl or arylalkyl, S(O) X , wherein x is 0, 1 or 2, acyl, amido or heterocyclyl; or B is N;
  • R 13 when R 13 is a heterocyclyl of the formula (a), Y can be N.
  • R’ 3 when R’ 3 is a heterocyclyl of the formula (a), at least two of W, X, Y, and Z is N.
  • the compounds of the formula (IV) can be compounds of the formulae:
  • the compounds of the formula (IV) can be compounds of the formulae: 48 polymorph, prodrug, solvate or clathrate thereof.
  • the compounds of the formula (IV) when FV 3 Is a heterocyclyl of the formula (f), Y can be N. Alternatively, when R i3 Is a heterocyclyl of the formula (f), at least two of W, X, Y, and Z Is N.
  • the compounds of the formula (IV) can be compounds of the formulae: polymorph, prodrug, solvate or clathrate thereof.
  • the disclosure also relates to compounds of the formula (V): or a pharmaceutically acceptable salt, polymorph, prodrug, solvate or clathrate thereof, wherein: n is 0, 1 or 2; each G is independently alkyl (e.g., CH 2 ) or C(O);
  • R 7 and R 8 are each independently halo, a carbon with at least one halo (e.g., one to three halo, such as CHF 2 , CCF 3 , CCI 3 ), alkyl, aryl, acyl or heterocyclyl; or
  • R 7 and R 8 together with the nitrogen atom to which they are attached, can form a heterocyclyl
  • R 13 is a heterocyclyl group of the formula: wherein W is N or C-FV 4 ; X is N or C-FV 4 ; Y is N or C-FV 4 ; and Z is N or C-R 14 ; wherein R' 4 is hydrogen, an electron withdrawing group, alkyl, cycloalkyl, aryl, heteroaryl, acyl, amido or heterocyclyl, wherein each aryl or heteroaryl is optionally substituted with halo, amino, OR 7 , wherein R 7 is hydrogen, alkyl, cycloalkyl, aryl or arylaikyl, S(O) X , wherein x is 0, 1 or 2, acyl, amido or heterocyclyl;
  • R 4 is alkyl, cycloalkyl, aryl, heteroaryl, halo, amino, OR 7 , wherein R 7 is hydrogen, alkyl, cycloalkyl, aryl or arylalkyl, S(O) X , wherein x is 0, 1 or 2, acyl, amido or heterocyclyl; and p is 0, 1 , 2, 3 or 4; wherein A is S(O) X , wherein x is 0, 1 or 2; O; C-R 14 , wherein R 14 is hydrogen, alkyl, cycloalkyl, aryl, heteroaryl, acyl, amido or heterocyclyl, wherein each aryl or heteroaryl is optionally substituted with halo, amino, OR 7 , wherein R 7 is hydrogen, alkyl, cycloalkyl, aryl or arylaikyl, S(O) X , wherein x is 0, 1 or 2, acyl, amido or heterocyclyl
  • B is C-R' 4 , wherein R 14 is hydrogen, an electron withdrawing group, alkyl, cycloalkyl, aryl, heteroaryl, acyl, amido or heterocyclyl, wherein each aryl or heteroaryl is optionally substituted with halo, amino, OR 7 , wherein R 7 is hydrogen, alkyl, cycloalkyl, aryl or arylalkyl, S(O) Xs wherein x is 0, 1 or 2, acyl, amido or heterocyclyl; or B is N; [0038]
  • R 13 when R 13 is a heterocyclyl of the formula (a), Y can be N.
  • R 13 is a heterocyclyl of the formula (a)
  • at least two of W, X, Y, and Z is N.
  • the compounds of the formula (V) can be compounds of the formulae:
  • the compounds of the formula (V) when R 13 Is a heterocyclyl of the formula (b), Y can be N. Alternatively, when R 13 Is a heterocyclyl of the formula (b), at least two of W, X, Y, and Z is N.
  • the compounds of the formula (V) can be compounds of the formulae: P ⁇ ⁇ IS2O21/04544S pharmaceutically acceptable salt, polymorph, prodrug, solvate or clathrate thereof.
  • R 13 when R 13 is a heterocyclyl of the formula (d), Y can be N.
  • R 13 when R 13 is a heterocyclyl of the formula (d), at least two of W, X, Y, and Z is N.
  • the compounds of the formula (V) can be compounds of the formulae:
  • R 13 when R 13 is a heterocyclyl of the formula (f), Y can be N.
  • R i3 is a heterocyclyl of the formula (f), at least two of W, X, Y, and Z is N.
  • the compounds of the formula (V) can be compounds of the formulae: y acceptable salt, polymorph, prodrug, solvate or clathrate thereof.
  • the disclosure also relates to compounds of the formula (VI): (VI) or a pharmaceutically acceptable salt, polymorph, prodrug, solvate or clathrate thereof, wherein: n is 0, 1 or 2; each G is independently alkyl (e.g., CH 2 ) or C(O); and
  • R 16 is alkyl, haloalkyi, cycloalkyi, aryl, heteroaryi, halo, amino, OR 7 , wherein R 7 is hydrogen, alkyl, cycloalkyi, aryl or arylalkyi, S(O) X , wherein x is 0, 1 or 2, acyl, amido or heterocyclyl; and p is 0, 1 , 2, 3 or 4; wherein X 7 is N or C-R' 8 ; wherein R 18 is hydrogen, an electron withdrawing group, alkyl, cycloalkyi, aryl, heteroaryl, acyl, amido or heterocyclyl, wherein each aryl or heteroaryi is optionally substituted with halo, amino, OR 7 , wherein R 7 is hydrogen, alkyl, cycloalkyi, aryl or arylalkyl, S(O) X , wherein x is 0, 1 or 2, acyl, amido or heterocyclyl; and
  • R 16 is alkyl, haloalkyi, cycloalkyi, aryl, heteroaryl, halo, amino, OR 7 , wherein R 7 is hydrogen, alkyl, cycloalkyi, aryl or arylalkyl, S(O) X , wherein x is 0, 1 or 2, acyl, amido or heterocyclyl; and p is 0, 1 , 2, 3 or 4; wherein X ; is N or C-R , wherein R 18 is hydrogen, an electron withdrawing group, alkyl, cycloalkyl, aryl, heteroaryl, acyl, amido or heterocyclyl, wherein each aryl or heteroaryl is optionally substituted with halo, amino, OR 7 , wherein R 7 is hydrogen, alkyl, cycloalkyl, aryl or arylalkyl, S(O) X , wherein x is 0, 1 or 2, acyl,
  • R 16 is alkyl, haioaikyl, cycloalkyl, aryl, heteroaryl, halo, amino, OR 7 , wherein R 7 is hydrogen, aikyl, cycloalkyl, aryi or aryialkyl, S(O) X , wherein x is 0, 1 or 2, acyl, amido or heterocyclyl; and p is 0, 1 , 2, 3 or 4;
  • Y is N or C-R 14 ; and Z is N or C-R 14 ; wherein R 14 is hydrogen, an electron withdrawing group, alkyl, cycloalkyl, aryl, heteroaryl, acyl, amido or heterocyclyl, wherein each aryl or heteroaryl is optionally substituted with halo, amino, OR 7 , wherein R 7 is hydrogen, alkyl, cycloalkyl, aryl or arylalkyl, S(O) X , wherein x is 0, 1 or 2, acyl, amido or heterocyclyl; , ein R 19 is H, alkyi or aryl or X 8 is C(R 18 )2; wherein each R 18 is independently hydrogen, an electron withdrawing group, aikyl, cycloalkyl, aryl, heteroaryl, acyl, amido or heterocyclyl, wherein each aryl or heteroaryl is optionally substituted with halo, amino, OR 7 , wherein
  • R 1S is alkyl, haioaikyl, cycloalkyl, aryl, heteroaryl, halo, amino, OR 7 , wherein R 7 is hydrogen, alkyl, cycloalkyl, aryl or aryialkyl, S(O) X , wherein x is 0, 1 or 2, acyl, amido or heterocyclyl; and p is 0, 1 , 2, 3 or 4;
  • Y is N or C-R 14 ; and Z is N or C-R 14 ; wherein R 14 is hydrogen, an electron pc; withdrawing group, alkyl, cycloalkyl, aryl, heteroaryl, acyl, amido or heterocyclyl, wherein each aryl or heteroaryl is optionally substituted with halo, amino, OR 7 , wherein R 7 is hydrogen, alkyl, cycloalkyl, aryl or aryialkyl, S(O) X , wherein x is 0, 1 or 2, acyl, amido or heterocyclyl;
  • R 1b groups of the formula (i) include:
  • compositions comprising one or more compounds and one or more pharmaceutically acceptable excipients.
  • a “pharmaceutical composition” refers to a chemical or biological composition suitable for administration to a subject (e.g., mammal).
  • compositions can be specifically formulated for administration via one or more of a number of routes, including but not limited to buccal, cutaneous, epicutaneous, epidural, infusion, inhalation, intraarterial, intracardial, intracerebroventricular, intradermal, intramuscular, intranasal, intraocular, intraperitoneal, intraspinal, intrathecal, intravenous, oral, parenteral, pulmonary, rectaiiy via an enema or suppository, subcutaneous, subdermal, sublingual, transdermal, and transmucosal.
  • administration can by means of capsule, drops, foams, gel, gum, injection, liquid, patch, pill, porous pouch, powder, tablet, or other suitable means of administration.
  • a “pharmaceutical excipient” or a “pharmaceutically acceptable excipient” is a carrier, sometimes a liquid, in which an active therapeutic agent is formulated.
  • the excipient generally does not provide any pharmacological activity to the formulation, though it can provide chemical and/or biological stability, and release characteristics. Examples of suitable formulations can be found, for example, in Remington, The Science And Practice of Pharmacy, 20th Edition, (Gennaro, A. R., Chief Editor), Philadelphia College of Pharmacy and Science, 2000, which is incorporated by reference in its entirety.
  • pharmaceutically acceptable carrier includes, but is not limited to, any and all solvents, dispersion media, coatings, antibacterial and antifungal agents, isotonic and absorption delaying agents that are physiologically compatible.
  • the carrier is suitable for parenteral administration.
  • the carrier can be suitable for intravenous, intraperitoneal, intramuscular, sublingual, or oral administration.
  • Pharmaceutically acceptable carriers include sterile aqueous solutions or dispersions and sterile powders for the extemporaneous preparation of sterile injectable solutions or dispersion. The use of such media and agents for pharmaceutically active substances is well known in the art. Except insofar as any conventional media or agent is incompatible with the active compound, use thereof in the pharmaceutical compositions of the invention is contemplated. Supplementary active compounds can also be incorporated into the compositions.
  • compositions can be sterile and stable under the conditions of manufacture and storage.
  • the composition can be formulated as a solution, microemulsion, liposome, or other ordered structure suitable to high drug concentration.
  • the carrier can be a solvent or dispersion medium containing, for example, water, ethanol, polyol (e.g., glycerol, propylene glycol, and liquid polyethylene glycol), and suitable mixtures thereof.
  • the proper fluidity can be maintained, for example, by the use of a coating such as lecithin, by the maintenance of the required particle size in the case of dispersion and by the use of surfactants.
  • isotonic agents for example, sugars, polyalcohols such as mannitol, sorbitol, or sodium chloride in the composition.
  • Prolonged absorption of injectable compositions can be brought about by including in the composition an agent which delays absorption, for example, monostearate salts and gelatin.
  • the compounds described herein can be formulated in a time release formulation, for example in a composition that includes a slow release polymer.
  • the active compounds can be prepared with carriers that will protect the compound against rapid release, such as a controlled release formulation, including implants and microencapsulated delivery systems.
  • Biodegradable, biocompatible polymers can be used, such as ethylene vinyl acetate, polyanhydrides, polyglycolic acid, collagen, polyorthoesters, polylactic acid and polylactic, polyglycolic copolymers (PLG). Many methods for the preparation of such formulations are known to those skilled in the art.
  • compositions of the present invention can be orally administered as a capsule (hard or soft), tablet (film coated, enteric coated or uncoated), powder or granules (coated or uncoated) or liquid (solution or suspension).
  • the formulations can be conveniently prepared by any of the methods 'well-known in the art.
  • the pharmaceutical compositions of the present invention can include one or more suitable production aids or excipients including fillers, binders, disintegrants, lubricants, diluents, flow agents, buffering agents, moistening agents, preservatives, colorants, sweeteners, flavors, and pharmaceutically compatible carriers.
  • the compounds can be administered by a variety of dosage forms as known in the art. Any biological ly- acceptable dosage form known to persons of ordinary skill in the art, and combinations thereof, are contemplated. Examples of such dosage forms include, without limitation, chewable tablets, quick dissolve tablets, effervescent tablets, reconstitutabie powders, elixirs, liquids, solutions, suspensions, emulsions, tablets, multi-layer tablets, bi-iayer tablets, capsules, soft gelatin capsules, hard gelatin capsules, capiets, lozenges, chewable lozenges, beads, powders, gum, granules, particles, microparticles, dispersible granules, cachets, douches, suppositories, creams, topicais, inhalants, aerosol inhalants, patches, particle inhalants, implants, depot implants, ingestibies, iniectabies (including subcutaneous, intramuscular, intravenous
  • Other compounds which can be included by admixture are, for example, medically inert ingredients (e.g., solid and liquid diluent), such as lactose, dextrosesaccharose, cellulose, starch or calcium phosphate for tablets or capsules, olive oil or ethyl oleate for soft capsules and water or vegetable oil for suspensions or emulsions; lubricating agents such as silica, talc, stearic acid, magnesium or calcium stearate and/or polyethylene glycols; gelling agents such as colloidal clays; thickening agents such as gum tragacanth or sodium alginate, binding agents such as starches, arable gums, gelatin, methylceliuiose, carboxymethylcellulose or polyvinylpyrrolidone; disintegrating agents such as starch, alginic acid, alginates or sodium starch glycolate; effervescing mixtures; dyestuff; sweeteners; weting agents such
  • Liquid dispersions for oral administration can be syrups, emulsions, solutions, or suspensions.
  • the syrups can contain as a carrier, for example, saccharose or saccharose with glycerol and/or mannitol and/or sorbitol.
  • the suspensions and the emulsions can contain a carrier, for example a natural gum, agar, sodium alginate, pectin, methylcellulose, carboxymethylcellulose, or polyvinyl alcohol.
  • the amount of active compound in a therapeutic composition can vary according to factors such as the disease state, age, gender, weight, patient history, risk factors, predisposition to disease, administration route, pre-existing treatment regime (e.g., possible interactions with other medications), and weight of the subject. Dosage regimens can be adjusted to provide the optimum therapeutic response. For example, a single bolus can be administered, several divided doses can be administered over time, or the dose can be proportionally reduced or increased as indicated by the exigencies of therapeutic situation.
  • a “dosage unit form,” as used herein, refers to physically discrete units suited as unitary dosages for the mammalian subjects to be treated; each unit containing a predetermined quantity of active compound calculated to produce the desired therapeutic effect in association with the required pharmaceutical carrier.
  • the specification for the dosage unit forms of the invention are dictated by and directly dependent on the unique characteristics of the active compound and the particular therapeutic effect to be achieved, and the limitations inherent in the art of compounding such an active compound for the treatment of sensitivity in subjects.
  • the compounds of the present invention can be administered in an effective amount.
  • the dosages as suitable for this invention can be a composition, a pharmaceutical composition or any other compositions described herein.
  • the dosage is typically administered once, twice, or thrice a day, although more frequent dosing intervals are possible.
  • the dosage can be administered every day, every 2 days, every 3 days, every 4 days, every 5 days, every 6 days, and/or every 7 days (once a week).
  • the dosage can be administered daily for up to and including 30 days, preferably between 7-10 days.
  • the dosage can be administered twice a day for 10 days. If the patient requires treatment for a chronic disease or condition, the dosage can be administered for as long as signs and/or symptoms persist.
  • the patient can require "maintenance treatment" where the patient is receiving dosages every day for months, years, or the remainder of their lives.
  • the composition of this invention can be to effect prophylaxis of recurring symptoms.
  • the dosage can be administered once or twice a day to prevent the onset of symptoms in patients at risk, especially for asymptomatic patients.
  • the absolute weight of a given compound included in a unit dose for administration to a subject can vary widely. For example, about 0.0001 to about 1 g, or about 0.001 to about 0.5 g, of at least one compound of this disclosure, or a plurality of compounds can be administered.
  • the unit dosage can vary from about 0.001 g to about 2g, from about 0.005 g to about 0.5 g, from about 0.01 g to about 0.25 g, from about 0.02 g to about 0.2 g, from about 0.03 g to about 0.15 g, from about 0.04 g to about 0.12 g, or from about 0.05 g to about 0.1 g.
  • Daily doses of the compounds can vary as well. Such daily doses can range, for example, from about 0.01 g/day to about 10 g/day, from about 0.02 g/day to about 5 g/day, from about 0.03 g/day to about 4 g/day, from about 0.04 g/day to about 3 g/day, from about 0.05 g/day to about 2 g/day, and from about 0.05 g/day to about 1 g/day.
  • the amount of compound(s) for use in treatment wiil vary not only with the particular carrier selected but aiso with the route of administration, the nature of the condition being treated, and the age and condition of the patient. Ultimately the attendant health care provider may determine proper dosage.
  • compositions described herein can be administered in any of the following routes: buccal, epicutaneous, epidural, infusion, inhalation, intraarterial, intracardial, intracerebroventricular, intradermal, intramuscular, intranasal, intraocular, intraperitoneal, intraspinal, intrathecal, intravenous, oral, parenteral, pulmonary, rectally via an enema or suppository, subcutaneous, subdermal, sublingual, transdermai, and transmucosal.
  • routes of administration are buccal and oral.
  • the administration can be local, where the composition is administered directly, close to, in the locality, near, at, about, or in the vicinity of, the site(s) of disease, e.g., inflammation, or systemic, wherein the composition is given to the patient and passes through the body widely, thereby reaching the site(s) of disease.
  • Local administration can be administration to, for example, tissue, organ, and/or organ system, which encompasses and/or is affected by the disease, and/or where the disease signs and/or symptoms are active or are likely to occur.
  • Administration can be topical with a local effect, composition is applied directly where its action is desired.
  • Administration can be enteral wherein the desired effect is systemic (non-locai), composition is given via the digestive tract.
  • Administration can be parenteral, where the desired effect is systemic, composition is given by other routes than the digestive tract.
  • compositions can include the compounds described herein in a “therapeutically effective amount;' Such a therapeutically effective amount is an amount sufficient to obtain the desired physiological effect, such as a reduction of at least one symptom of cancer or an inflammatory disease or condition.
  • compositions contemplated herein can contain other ingredients such as chemotherapeutic agents, anti-inflammatory agents, antiviral agents, antibacterial agents, antimicrobial agents, immunomodulatory drugs, such as lenalidomide, pomaiidomide or thalidomide, histone deacetylase inhibitors, such as panobinostat, preservatives or combinations thereof.
  • chemotherapeutic agents anti-inflammatory agents
  • antiviral agents antibacterial agents
  • antimicrobial agents antimicrobial agents
  • immunomodulatory drugs such as lenalidomide, pomaiidomide or thalidomide
  • histone deacetylase inhibitors such as panobinostat, preservatives or combinations thereof.
  • This disclosure also includes methods for treating neurodegenerative diseases, such as Parkinson’s disease, Alzheimer’s disease, Huntington's disease, and ALS, comprising administering a therapeutically effective amount of at least one of the compounds described herein (e.g., compounds of the formulae (I), (la)-(lk), (II), (III), (IV), (V), and (VI)) to a subject in need thereof.
  • neurodegenerative diseases such as Parkinson’s disease, Alzheimer’s disease, Huntington's disease, and ALS
  • This disclosure aiso includes methods for reducing, substantially eliminating or eliminating dysregulation of proteostasis comprising administering a therapeutically effective amount of at least one of the compounds described herein (e.g., compounds of the formulae (I), (la)-(lk), (II), (III), (IV), (V), and (VI)) to a subject in need thereof.
  • a therapeutically effective amount of at least one of the compounds described herein e.g., compounds of the formulae (I), (la)-(lk), (II), (III), (IV), (V), and (VI)
  • This disclosure also includes methods for reducing, substantially eliminating or eliminating the accumulation of intrinsically disordered proteins (e.g., a-syn) comprising administering a therapeutically effective amount of at least one of the compounds described herein (e.g., compounds of the formulae compounds of the formulae (I), (ia)-(lk), (II), (III), (IV), (V), and (VI)) to a subject in need thereof.
  • a-syn e.g., compounds of the formulae compounds of the formulae (I), (ia)-(lk), (II), (III), (IV), (V), and (VI)
  • the terms “treat” and “treating” are not limited to the case where the subject (e.g. patient) is cured and the disease is eradicated. Rather, treatment that merely reduces symptoms, and/or delays disease progression is also contemplated.
  • the pharmaceutical compositions disclosed herein can have the ability to effectively treat new patient segments where proteasome inhibition and reduced toxicity is desired or warranted.
  • the compounds and methods described herein can be used prophylactically or therapeutically.
  • the term “prophylactic” or “therapeutic” treatment refers to administration of a drug to a host before or after onset of a disease or condition. If it is administered prior to clinical manifestation of the unwanted condition (e.g., disease or other unwanted state of the host animal) then the treatment is prophylactic, i.e., it protects the host against developing the unwanted condition, whereas if administered after manifestation of the unwanted condition, the treatment is therapeutic (i.e., it is intended to diminish, ameliorate or maintain the existing unwanted condition or side effects therefrom).
  • Administering the compounds described herein (including enantiomers and salts thereof) is contemplated in both a prophylactic treatment (e.g. to patients at risk for disease, such as elderly patients who, because of their advancing age, are at risk for arthritis, cancer, and the like) and therapeutic treatment (e.g. to patients with symptoms of disease or to patients diagnosed with disease).
  • therapeutically effective amount refers to that amount of one or more compounds of the various examples of the present invention that elicits a biological or medicinal response in a tissue system, animal or human, that is being sought by a researcher, veterinarian, medical doctor or other clinician, which includes alleviation of the symptoms of the disease or disorder being treated.
  • the therapeutically effective amount is that which can treat or alleviate the disease or symptoms of the disease at a reasonable benefit/risk ratio applicable to any medical treatment.
  • the total daily usage of the compounds and compositions described herein can be decided by the attending physician within the scope of sound medical judgment.
  • the specific therapeuticaily-effective dose level for any particular patient will depend upon a variety of factors, including the condition being treated and the severity of the condition; activity of the specific compound employed; the specific composition employed; the age, body weight, general health, gender and diet of the patient: the time of administration, route of administration, and rate of excretion of the specific compound employed; the duration of the treatment; drugs used in combination or coincidentally with the specific compound employed; and like factors well known to the researcher, veterinarian, medical doctor or other clinician. It is also appreciated that the therapeutically effective amount can be selected with reference to any toxicity, or other undesirable side effect, that might occur during administration of one or more of the compounds described herein.
  • alkyl refers to substituted or unsubstituted straight chain, branched and cyclic, saturated mono- or bi-varriing groups having from 1 to 20 carbon atoms, 10 to 20 carbon atoms, 12 to 18 carbon atoms, 6 to about 10 carbon atoms, 1 to 10 carbons atoms, 1 to 8 carbon atoms, 2 to 8 carbon atoms, 3 to 8 carbon atoms, 4 to 8 carbon atoms, 5 to 8 carbon atoms, 1 to 6 carbon atoms, 2 to 6 carbon atoms, 3 to 6 carbon atoms, or 1 to 3 carbon atoms.
  • Examples of straight chain mono-valent (Ci-C2o)-alkyl groups include those with from 1 to 8 carbon atoms such as methyl (i.e., CH 3 ), ethyl, n- propyl, n-butyl, n-pentyl, n-hexyl, n-heptyl, n-octyl groups.
  • Examples of branched mono-valent (Ci-C 20 )-alkyl groups include isopropyl, iso-butyl, sec-butyl, t-butyl, neopentyl, and isopentyl.
  • Examples of straight chain bi-valent (CrC 2 o)alkyl groups include those with from 1 to 6 carbon atoms such as -CH 2 -, -CH 2 CH 2 -, -CH 2 CH 2 CH 2 -, -CH 2 CH 2 CH 2 CH 2 -, and -CH 2 CH 2 CH 2 CH 2 CH 2 -.
  • Examples of branched bi-valent alkyl groups include ⁇ CH(CH 3 )CH 2 - and -CH 2 CH(CH 3 )CH 2 -.
  • cyclic aikyl groups include cyclopropyl, cyclobutyl, cyclopently, cyclohexyl, cyclooctyl, bicycio[l .1 .1]pentyl, bicyclo[2.1 .1 Jhexyl, and bicyclo[2.2.1 Jheptyi.
  • Cycloalkyl groups further include polycyclic cycioaikyl groups such as, but not limited to, norbornyl, adamantyl, bornyl, camphenyl, isocamphenyl, and carenyl groups, and fused rings such as, but not limited to, decalinyl, and the like.
  • alkyl includes a combination of substituted and unsubstituted alkyl.
  • alkyl, and also (Ci)alkyl includes methyl and substituted methyl.
  • (Ci)alkyl includes benzyl.
  • alkyl can include methyl and substituted (C 2 -C 3 )alkyl.
  • Alkyl can also include substituted methyl and unsubstituted (C 2 -Cg)alkyl.
  • alkyl can be methyl and C 2 -C 3 linear alkyl.
  • alkyl can be methyl and C 2 -Cs branched alkyl.
  • methyl is understood to be -CH 3 , which is not substituted.
  • methylene is understood to be -CH 2 -, which is not substituted.
  • (Ci )alkyl is understood to be a substituted or an unsubstituted -CH 3 or a substituted or an unsubstituted -CH 2 -.
  • Representative substituted alkyl groups can be substituted one or more times with any of the groups listed herein, for example, cycioaikyl, heterocyciyl, aryl, amino, ha loaiky I, hydroxy, cyano, carboxy, nitro, thio, alkoxy, and halogen groups.
  • representative substituted alkyl groups can be substituted one or more fluoro, chloro, bromo, iodo, amino, amido, alkyl, alkoxy, alkylamido, alkenyl, alkynyl, alkoxycarbonyl, acyl, formyl, arylcarbonyl, aryloxycarbonyl, aryioxy, carboxy, naioaikyl, hydroxy, cyano, nitroso, nitro, azido, trifluoromethyl, trifluoromethoxy, thio, aikylthio, aryithioi, alkylsulfonyl, alkylsulfinyl, dialkylaminosulfonyl, sulfonic acid, carboxylic acid, dialkylamino and dialkylamido.
  • representative substituted alkyl groups can be substituted from a set of groups including amino, hydroxy, cyano, carboxy, nitro, thio and alkoxy, but not including halogen groups.
  • alkyl can be substituted with a non-halogen group.
  • representative substituted alkyl groups can be substituted with a fluoro group, substituted with a bromo group, substituted with a halogen other than bromo, or substituted with a halogen other than fluoro.
  • representative substituted alkyl groups can be substituted with one, two, three or more fluoro groups or they can be substituted with one, two, three or more non-fluoro groups.
  • alkyl can be trifluoromethyl, difluoromethyl, or fluoromethyl, or alkyl can be substituted alkyl other than trifiuoromethyi , difluoromethyl or fiuoromethyi.
  • Alkyl can be haloalkyi or alkyl can be substituted alkyl other than haloalkyi.
  • alkyl also generally refers to alkyl groups that can comprise one or more heteroatoms in the carbon chain. Thus, for example, “alkyl” also encompasses groups such as ⁇ [(CH 2 ) P O]qH and the like.
  • alkenyl refers to substituted or unsubstituted straight chain, branched and cyclic, saturated mono- or bi-valent groups having at least one carbon-carbon double bond and from 2 to 20 carbon atoms, 10 to 20 carbon atoms, 12 to 18 carbon atoms, 6 to about 10 carbon atoms, 2 to 10 carbons atoms, 2 to 8 carbon atoms, 3 to 8 carbon atoms, 4 to 8 carbon atoms, 5 to 8 carbon atoms, 2 to 6 carbon atoms, 3 to 6 carbon atoms, 4 to 6 carbon atoms, 2 to 4 carbon atoms, or 2 to 3 carbon atoms.
  • the double bonds can be be trans or cis orientation.
  • the double bonds can be terminal or internal.
  • the alkenyl group can be attached via the portion of the alkenyl group containing the double bond, e.g., vinyl, propen-1 -yl and buten-1 -yl, or the alkenyl group can be attached via a portion of the alkenyl group that does not contain the double bond, e.g., penten-4-yi.
  • Examples of mono-valent (C2-C2o)-alkenyl groups include those with from 1 to 8 carbon atoms such as vinyl, propenyl, propen-1 -yi, propen-2 -yl, butenyl, buten-1 -yl, buten-2-yl, sec-buten-1 -yi, sec-buten-3-yi, pentenyl, hexenyl, heptenyl and octenyl groups.
  • Examples of branched mono- valent (C2-C2o)-alkenyl groups include isopropenyl, iso-butenyl, sec-butenyl, t- butenyl, neopentenyl, and isopentenyl.
  • Examples of straight chain bi-vending (C 2 - C2o)aikenyl groups include those with from 2 to 6 carbon atoms such as -CHCH- , -CHCHCHa-, -CHCHCH 2 CH 2 -, and -GHCHGH 2 GH 2 GH 2 -.
  • Examples of branched bi-valent alkyl groups include -CfCHaJCH- and “CHC(CH 3 )CH 2 -.
  • Examples of cyclic alkenyl groups include cyclopentenyl, cyclohexenyl and cyclooctenyl. It is envisaged that alkenyl can also include masked alkenyl groups, precursors of alkenyl groups or other related groups.
  • substituted alkenyl also includes alkenyl groups which are substantially tautomeric with a non-alkenyl group.
  • substituted alkenyl can be 2-aminoalkenyl, 2-alkylaminoalkenyl, 2-hydroxyalkenyl, 2- hydroxyvinyl, 2-hydroxypropenyl, but substituted alkenyl is also understood to include the group of substituted alkenyl groups other than alkenyl which are tautomeric with non-alkenyl containing groups.
  • alkenyl can be understood to include a combination of substituted and unsubstituted alkenyl.
  • alkenyl can be vinyl and substituted vinyl.
  • alkenyl can be vinyl and substituted (Cs-Csjalkenyl.
  • Alkenyl can also include substituted vinyl and unsubstituted (Cs-Cslalkenyl.
  • Representative substituted alkenyl groups can be substituted one or more times with any of the groups listed herein, for example, monoalkylamino, dialkylamino, cyano, acetyl, amido, carboxy, nitro, alkylthio, alkoxy, and halogen groups.
  • representative substituted alkenyl groups can be substituted one or more fluoro, chloro, bromo, iodo, amino, amido, alkyl, alkoxy, alkylamido, alkenyl, alkynyl, alkoxycarbonyl, acyl, formyl, arylcarbonyl, aryloxycarbonyl, aryloxy, carboxy, haloalkyl, hydroxy, cyano, nitroso, nitro, azido, trifluoromethyl, trifluoromethoxy, thio, alkylthio, arylthiol, alkylsulfonyl, alkylsulfinyl, dialkylaminosulfonyl, sulfonic acid, carboxylic acid, dialkylamino and dialkylamido.
  • representative substituted alkenyl groups can be substituted from a set of groups including monoalkylamino, dialkylamino, cyano, acetyl, amido, carboxy, nitro, alkylthio and alkoxy, but not including halogen groups.
  • alkenyl can be substituted with a non-halogen group.
  • representative substituted alkenyl groups can be substituted with a fluoro group, substituted with a bromo group, substituted with a halogen other than bromo, or substituted with a halogen other than fluoro.
  • alkenyl can be 1 -fluorovinyl, 2-fluorovinyl, 1 ,2-difluorovinyl, 1 ,2,2-trifluorovinyl, 2,2- difluorovinyl, trifluoropropen-2-yl, 3,3,3-trifluoropropenyl, 1 -fluoropropenyl, 1- chlorovinyl, 2-chlorovinyl, 1 ,2-dichlorovinyl, 1 ,2,2-trichlorovinyl or 2,2- dichlorovinyl.
  • representative substituted alkenyl groups can be substituted with one, two, three or more fluoro groups or they can be substituted with one, two, three or more non-fluoro groups.
  • aikynyi refers to substituted or unsubstituted straight and branched chain alkyl groups, except that at least one triple bond exists between two carbon atoms.
  • aikynyi groups have from 2 to 50 carbon atoms, 2 to 20 carbon atoms, 10 to 20 carbon atoms, 12 to 18 carbon atoms, 6 to about 10 carbon atoms, 2 to 10 carbons atoms, 2 to 8 carbon atoms, 3 to 8 carbon atoms, 4 to 8 carbon atoms, 5 to 8 carbon atoms, 2 to 6 carbon atoms, 3 to 6 carbon atoms, 4 to 6 carbon atoms, 2 to 4 carbon atoms, or 2 to 3 carbon atoms.
  • aryl refers to substituted or unsubstituted univalent groups that are derived by removing a hydrogen atom from an arene, which is a cyclic aromatic hydrocarbon, having from 6 to 20 carbon atoms, 10 to 20 carbon atoms, 12 to 20 carbon atoms, 6 to about 10 carbon atoms or 6 to 8 carbon atoms.
  • Examples of (Ci 3 -C 20 )aryi groups include phenyl, napthalenyl, azulenyl, biphenylyl, indacenyl, fluorenyl, phenanthrenyl, triphenylenyl, pyrenyl, naphthacenyl, chrysenyl, anthracenyl groups.
  • Examples include substituted phenyl, substituted napthalenyl, substituted azulenyl, substituted biphenylyl, substituted indacenyl, substituted fluorenyl, substituted phenanthrenyl, substituted triphenylenyl, substituted pyrenyl, substituted naphthacenyl, substituted chrysenyl, and substituted anthracenyl groups.
  • Examples also include unsubstituted phenyl, unsubstituted napthalenyl, unsubstituted azulenyl, unsubstituted biphenylyl, unsubstituted indacenyl, unsubstituted fluorenyl, unsubstituted phenanthrenyl, unsubstituted triphenylenyl, unsubstituted pyrenyl, unsubstituted naphthacenyl, unsubstituted chrysenyl, and unsubstituted anthracenyl groups.
  • Aryl includes phenyl groups and also nonphenyl aryl groups.
  • (Cs-C2o)aryl encompasses mono- and polycyclic (C 6 -C 20 )aryl groups, including fused and nonfused polycyclic (C 6 -C 20 )aryl groups.
  • heterocyclyl refers to substituted aromatic, unsubstituted aromatic, substituted non-aromatic, and unsubstituted non-aromatic rings containing 3 or more atoms in the ring, of which, one or more is a heteroatom such as, but not limited to, N, O, and S.
  • a heterocyclyl can be a cycloheteroalkyl, or a heteroaryl, or If polycyclic, any combination thereof.
  • heterocyclyl groups include 3 to about 20 ring members, whereas other such groups have 3 to about 15 ring members.
  • heterocyclyl groups include heterocyclyl groups that include 3 to 8 carbon atoms (C 3 -C 8 ), 3 to 6 carbon atoms (C 3 -C 6 ) or 6 to 8 carbon atoms (C 6 - C 8 ).
  • a heterocyclyl group designated as a C 2 -heterocyclyl can be a 5-membered ring with two carbon atoms and three heteroatoms, a 6-membered ring with two carbon atoms and four heteroatoms and so forth.
  • a C4-heterocyclyl can be a 5-membered ring with one heteroatom, a 6-membered ring with two heteroatoms, and so forth.
  • heterocyclyl group includes fused ring species including those that include fused aromatic and non-aromatic groups.
  • heterocyclyl groups include, but are not limited to piperidynyl, piperazinyl, morpholinyl, furanyl, pyrroiidinyl, pyridinyl, pyrazinyl, pyrimidinyl, triazinyl, thiophenyl, tetra hydro furanyl, pyrrolyl, oxazolyl, imidazolyl, triazyolyl, tetrazolyl, benzoxazolinyi, and benzimidazolmyl groups.
  • heterocyclyl groups include, without limitation: represents H, (Ci-Ca))alkyl, (C 3 -C 20 )aryl or an amine protecting group (e.g., a t- butyloxycarbonyl group) and wherein the heterocyclyl group can be substituted or unsubstituted.
  • a nitrogen-containing heterocyclyl group is a heterocyclyl group containing a nitrogen atom as an atom in the ring.
  • the heterocyclyl is other than thiophene or substituted thiophene.
  • the heterocyclyl is other than furan or substituted furan.
  • alkoxy refers to an oxygen atom connected to an alkyl group, including a cycloalkyl group, as are defined herein.
  • alkoxy groups include but are not limited to methoxy, ethoxy, propoxy, butoxy, pentyloxy, hexyloxy, and the like.
  • branched alkoxy Include but are not limited to isopropoxy, sec-butoxy, tert-butoxy, isopentyloxy, isohexyloxy, and the like.
  • cyclic alkoxy examples include but are not limited to cyclopropyioxy, cyclobutyioxy, cyclopentyloxy, cyclohexyloxy, and the like.
  • An alkoxy group can include one to about 12-20 or about 12-40 carbon atoms bonded to the oxygen atom, and can further include double or triple bonds, and can aiso include heteroatoms.
  • alkyoxy also includes an oxygen atom connected to an alkyenyl group and oxygen atom connected to an alkynyl group.
  • an allyloxy group is an alkoxy group within the meaning herein.
  • a methoxyethoxy group is also an alkoxy group within the meaning herein, as is a methylenedioxy group in a context where two adjacent atoms of a structure are substituted therewith.
  • aryloxy refers to an oxygen atom connected to an aryl group as are defined herein.
  • aralkyl and arylalkyi refers to alkyl groups as defined herein in which a hydrogen or carbon bond of an alkyl group is replaced with a bond to an aryi group as defined herein.
  • Representative aralkyl groups include benzyl, biphenylmethyl and phenylethyl groups and fused (cycloaikyiaryl)alkyi groups such as 4-ethyi-indanyl.
  • Aralkenyl groups are alkenyl groups as defined herein in which a hydrogen or carbon bond of an alkyl group is replaced with a bond to an aryl group as defined herein.
  • halo means, unless otherwise stated, a fluorine, chlorine, bromine, or iodine atom.
  • amine and “amino” as used herein refers to a substituent of the form -NH2, -NHR, -NR2, -NR3 4 , wherein each R is independently selected, and protonated forms of each, except for -NR 3 + , which cannot be protonated. Accordingly, any compound substituted with an amino group can be viewed as an amine.
  • An “amino group” within the meaning herein can be a primary, secondary, tertiary, or quaternary amino group.
  • An “alkylamino” group includes a monoaikylamino, dialkylamino, and trialkylamino group.
  • acyl refers to a group containing a carbonyl moiety wherein the group is bonded via the carbonyl carbon atom.
  • the carbonyl carbon atom is aiso bonded to another carbon atom, which can be part of a substituted or unsubstituted alkyl, alkenyl, alkynyl, aryi, cycloalkyl, heterocyclyl, group or the like.
  • the term “formyl” as used herein refers to a group containing a carbonyl moiety wherein the group is bonded via the carbonyl carbon atom.
  • the carbonyl carbon atom is also bonded to a hydrogen atom.
  • alkoxycarbonyl refers to a group containing a carbonyl moiety wherein the group is bonded via the carbonyl carbon atom.
  • the carbonyl carbon atom is also bonded to an oxygen atom which is further bonded to an alkyl group.
  • Alkoxycarbonyl also includes the group where a carbonyl carbon atom is also bonded to an oxygen atom which is further bonded to an alkyenyl group.
  • Alkoxycarbonyl also includes the group where a carbonyl carbon atom is also bonded to an oxygen atom which is further bonded to an alkynyl group.
  • alkoxycarbonyl as the term is defined herein, and is also included in the term “aryloxycarbonyl,” the carbonyl carbon atom is bonded to an oxygen atom which is bonded to an aryl group instead of an alkyl group.
  • aryicarbonyl refers to a group containing a carbonyl moiety wherein the group is bonded via the carbonyl carbon atom.
  • the carbonyl carbon atom is also bonded to an aryl group.
  • alkyiamido refers to a group containing a carbonyl moiety wherein the group is bonded via the carbonyl carbon atom.
  • the carbonyl carbon atom is also bonded to a nitrogen group which is bonded to one or more alkyl groups.
  • the carbonyl carbon atom is bonded to a nitrogen atom which is bonded to one or more aryl group instead of, or in addition to, the one or more alkyl group.
  • the carbonyl carbon atom is bonded to an nitrogen atom which is bonded to one or more alkenyl group instead of, or in addition to, the one or more alkyl and or/aryl group.
  • the carbonyl carbon atom is bonded to a nitrogen atom which is bonded to one or more alkynyl group instead of, or in addition to, the one or more alkyl, alkenyl and/or aryl group.
  • carboxy refers to a group containing a carbonyl moiety wherein the group is bonded via the carbonyl carbon atom.
  • the carbonyl carbon atom is also bonded to a hydroxy group or oxygen anion so as to result in a carboxylic acid or carboxylate.
  • Carboxy also includes both the protonated form of the carboxylic acid and the salt form.
  • carboxy can be understood as COOH or CO 2 H.
  • amide as used herein resers to a group having the formula C(O)NRR, wherein R is defined herein and can each independently be, e.g., hydrogen, alkyl, aryl or each R, together with the nitrogen atom to which they are attached, form a heterocyclyl group.
  • alkylthio refers to a sulfur atom connected to an alkyl, alkenyl, or alkynyl group as defined herein.
  • aryithio refers to a sulfur atom connected to an aryl group as defined herein.
  • alkylsulfonyl refers to a sulfonyl group connected to an alkyl, alkenyl, or alkynyl group as defined herein.
  • alkylsulfinyl refers to a sulfinyl group connected to an alkyl, alkenyl, or alkynyl group as defined herein.
  • dialkylaminosulfonyl refers to a sulfonyl group connected to a nitrogen further connected to two alkyl groups, as defined herein, and which can optionally be linked together to form a ring with the nitrogen. This term also includes the group where the nitrogen is further connected to one or two alkenyl groups in place of the alkyl groups.
  • dialkylamino refers to an amino group connected to two alkyl groups, as defined herein, and which can optionally be linked together to form a ring with the nitrogen. This term also includes the group where the nitrogen is further connected to one or two alkenyl groups in place of the alkyl groups.
  • dialkylamido refers to an amido group connected to two aikyl groups, as defined herein, and which can optionally be linked together to form a ring with the nitrogen. This term also includes the group where the nitrogen is further connected to one or two alkenyl groups in place of the alkyl groups.
  • substituted refers to a group that is substituted with one or more groups including, but not limited to, the following groups: halogen (e.g., F, Ci, Br, and I), R, OR, ROH (e.g., CH 2 OH), OC(O)N(R) 2 (also known as carbamate), CN, NO, NO 2 , ONO2, azido, CF 3 , OCF3, methylenedioxy, ethyienedioxy, (Cs-C 20 )heteroaryl, N(R) 2 , Si(R) 3 , SR, SOR, SO2R, SO 2 N(R) 2 , SO3R, P(O)(OR) 2 , OP(O)(OR) 2I C(O)R, C(O)C(O)R, C(O)CH 2 C(O)R, C(S)R, C(O)OR, OC(O)R, C(CH)R, C(S)R, C(O)
  • Substituted also includes a group that is substituted with one or more groups including, but not limited to, the following groups: fluoro, chloro, bromo, iodo, amino, amido, alkyl, hydroxy, alkoxy, alkylamido, alkenyl, alkynyl, aikoxycarbonyl, acyl, formyl, arylcarbonyl, aryloxycarbonyl, aryloxy, carboxy, haloalkyi, hydroxy, cyano, nitroso, nitro, azido, trifiuoromethyl, trifluoromethoxy, thio, alkylthio, arylthiol, alkylsulfonyl, alkylsulfinyl, dialkyiaminosuifonyl, sulfonic acid, carboxylic acid, dialkylamino and dialkylamido.
  • groups including, but not limited to, the following groups: fluoro, chloro,
  • the substituents can be linked to form a carbocyclic or heterocyclic ring.
  • Such adjacent groups can have a vicinal or germinal relationship, or they can be adjacent on a ring in, e.g., an ortho-arrangement.
  • Each instance of substituted is understood to be independent.
  • a substituted aryl can be substituted with bromo and a substituted heterocycle on the same compound can be substituted with alkyl.
  • a substituted group can be substituted with one or more non-fluoro groups.
  • a substituted group can be substituted with one or more non-cyano groups.
  • a substituted group can be substituted with one or more groups other than haloalkyi.
  • a substituted group can be substituted with one or more groups other than tert-butyl.
  • a substituted group can be substituted with one or more groups other than trifiuoromethyl.
  • a substituted group can be substituted with one or more groups other than nitro, other than methyl, other than methoxymethyl, other than dialkyiaminosuifonyl, other than bromo, other than chloro, other than amido, other than halo, other than benzodioxepinyl, other than polycyclic heterocyciyl, other than polycyclic substituted aryl, other than methoxycarbonyl, other than alkoxycarbonyl, other than th iophenyi , or other than nitrophenyl, or groups meeting a combination of such descriptions.
  • substituted is also understood to include fluoro, cyano, haloalkyi, tert-butyl, trifiuoromethyl, nitro, methyl, methoxymethyl, dialkyiaminosuifonyl, bromo, chioro, amido, halo, benzodioxepinyl, polycyclic heterocyciyl, polycyclic substituted aryl, methoxycarbonyl, aikoxycarbonyl, thiophenyl, and nitrophenyl groups.
  • the compounds described herein can contain chiral centers. All diastereomers of the compounds described herein are contemplated herein, as well as racemates.
  • salts and “pharmaceutically acceptable salts” refer to derivatives of the disclosed compounds wherein the parent compound is modified by making acid or base salts thereof.
  • pharmaceutically acceptable salts include, but are not limited to, mineral or organic acid salts of basic groups such as amines; and alkali or organic salts of acidic groups such as carboxylic acids.
  • Pharmaceutically acceptable salts include the conventional non-toxic salts or the quaternary ammonium salts of the parent compound formed, for example, from non-toxic inorganic or organic acids.
  • such conventional non-toxic salts include those derived from inorganic acids such as hydrochloric, hydrobromic, sulfuric, sulfamic, phosphoric, and nitric; and the salts prepared from organic acids such as acetic, propionic, succinic, glycolic, stearic, lactic, malic, tartaric, citric, ascorbic, pamoic, maleic, hydroxymaleic, phenylacetic, glutamic, benzoic, salicylic, sulfanilic, 2- acetoxybenzoic, fumaric, toluenesulfonic, methanesulfonic, ethane disulfonic, oxalic, and isethionic, and the like.
  • inorganic acids such as hydrochloric, hydrobromic, sulfuric, sulfamic, phosphoric, and nitric
  • organic acids such as acetic, propionic, succinic, glycolic, stearic, lactic, malic
  • salts can be synthesized from the parent compound which contains a basic or acidic moiety by conventional chemical methods.
  • such salts can be prepared by reacting the free acid or base forms of these compounds with a stoichiometric (or larger) amount of the appropriate base or acid in water or in an organic solvent, or in a mixture of the two; generally, nonaqueous media like ether, ethyi acetate, ethanol, isopropanoi, or acetonitrile are preferred.
  • Lists of suitable salts are found in Remington's Pharmaceutical Sciences, 17th ed., Mack Publishing Company, Easton, Pa., 1985, the disclosure of which is hereby incorporated by reference.
  • solvate means a compound, or a salt thereof, that further includes a stoichiometric or non-stoich iometric amount of solvent bound by non-covalent intermolecular forces. Where the solvent is water, the solvate is a hydrate.
  • prodrug means a derivative of a compound that can hydrolyze, oxidize, or otherwise react under biological conditions (in vitro or in vivo) to provide an active compound, particularly a compound of the invention.
  • prodrugs include, but are not limited to, derivatives and metabolites of a compound of the invention that include biohydrolyzable moieties such as biohydrolyzable amides, biohydrolyzable esters, biohydrolyzable carbamates, biohydrolyzable carbonates, biohydrolyzabie ureides, and biohydrolyzable phosphate analogues.
  • Specific prodrugs of compounds with carboxyl functional groups are the lower alkyl esters of the carboxylic acid.
  • the carboxylate esters are conveniently formed by esterifying any of the carboxylic acid moieties present on the molecule.
  • Prodrugs can typically be prepared using well-known methods, such as those described by Burgers Medicinal Chemistry and Drug Discovery 6th ed. (Donald J. Abraham ed., 2001 , Wiley) and Design and Application of Prodrugs (H. Bundgaard ed., 1985, Harwood Academic Publishers GmbH).
  • the term “subject” or “patient” refers to any organism to which a composition described herein can be administered, e.g., for experimental, diagnostic, prophylactic and/or therapeutic purposes.
  • Subject refers to a mammal receiving the compositions disclosed herein or subject to disclosed methods. It is understood and herein contemplated that “mammal” includes but is not limited to humans, non-human primates, cows, horses, dogs, cats, mice, rats, rabbits, and guinea pigs.
  • substantially refers to a majority of, or mostly, as in at least about 50%, 60%, 70%, 80%, 90%, 95%, 96%, 97%, 98%, 99%, 99.5%, 99.9%, 99.99%, or at least about 99.999% or more.
  • the human proteasome is part of the cellular machinery that regulates protein degradation. Most proteins are degraded by the 26S proteasome via a ubiquitin-dependent mechanism, however intrinsically disordered proteins (unstructured) proteins can also be degraded the 20S isoform of the proteasome via a ubiquitin-independent mechanism. Intrinsically disordered proteins (IDPs) are named for their lack of tertiary structure allowing them to adopt numerous conformations and interact with multiple binding partners. When the synthesis of IDPs outpaces their rate of degradation, they accumulate and induce toxic signaling events that drive many human diseases.
  • IDPs Intrinsically disordered proteins
  • c-MYC pro-oncogenic transcription factor
  • Overexpression of c-MYC is the driving force in an astonishing 60-70% of all human cancers including multiple myeloma, histiocytic sarcoma, myeloid leukemia, glioblastoma, melanoma, breast cancer, coion cancer, cervical cancer, small-cell lung carcinoma, and osteosarcoma.
  • Small molecule 20S proteasome activators can reduce c-MYC protein levels and therefore prevent the initiation progression and relapse in c-MYC driven cancers.
  • the disclosure relates to small molecule 20S proteasome activators of the formulae (I), (la)-(lk), (II), (III), (IV), and (IV) as therapeutic agents to treat amyloidogenic diseases including neurodegenerative diseases and type II diabetes.
  • Neurodegenerative diseases include: Alzheimer’s disease (AD) and other dementias, Parkinson's disease (PD) and PD-related disorders, Prion disease, Motor neuron diseases (MND), Huntington's disease (HD), Spinocerebellar ataxia (SCA) and Spinal muscular atrophy (SMA).
  • IDPs intrinsically disordered proteins
  • DPR dipeptide repeat
  • Chlorpromazine activates all the CT-L sites of the 20S proteasome (FIG. 1 ) and achieved a doubling of activity (hereafter referred to as AC200) using the combination of probes at 13.5 pM (i.e. AC200 13.5 mM), with a maximum fold enhancement of nearly 4-fold (i.e. 400%). Moreover, chlorpromazine did not enhance the proteolytic activity of the 26S proteasome.
  • a non-substituted benzyl group (1) was synthesized by treating 2-chlorophenothiazine with NaH followed by (bromomethyl)-benzene (Scheme 1 ). This general procedure of deprotonating 2-chlorophenothiazine and then addition of a halogenated benzyl group was used to prepare compounds 2 - 7 (Scheme 1 ). The role of the aryl ester moiety in activating the 20S proteasome
  • the carboxylate derivative (6) was prepared by treating 2-chloro-phenothiazine with NaH and 4-(bromomethyl)phenyl acetate. Compound 6 was then treated with KOH to produce the alcohol derivative (8). Next, the impact of the size of the substituent was investigated by exchanging the methyl ester with a tert-butyl ester
  • Amide 11 was prepared via the nitrile intermediate (10) obtained by treating 2-chlorophenothazine with 5-bromovaleronitrile. The nitrile group was then converted to the amide in a 95% yield using an H2SO4 catalyzed hydrolysis (Scheme 2).
  • Scheme 2 shows the synthesis of compounds 10 and 1 1.
  • Amide 15 was then synthesized to compare the four-methylene linker to the two-methylene chain seen in CPZ. While compounds 11 and 15 were made to investigate the role of nitrogen on an aliphatic chain, both compounds have a primary nitrogen.
  • the amide was further modified to include additional substituents.
  • Compound 16 was designed to have a similar pendant to the parent compound CPZ, but with the dimethyl amine transformed to a dimethyl amide.
  • compound 19 was designed io mimic the di-substituted amine group of CPZ, but with an electron depleted nitrogen to prevent M- protonation.
  • the bis-fluorodiphenyl amine group was synthesized using a Chan- Lam-Evans like coupling that was previously reported. 7 ’
  • the bis-fluorodiphenyl amine was transformed to acrylamide 14 by treating it with acryloyl chloride and
  • the electron rich benzyl derivative, 9, is 3x less potent than its electron poor counterpart, 7. It has been reported that this “face-centered” stacking is often favored during this aromatic donor-acceptor interaction and the electron depletion impacts the strength of this stacking, the more electron deficient arenes stack very effectively to the electron-rich donor. 72 These findings strongly suggests that this TT-TF stacking is a key interaction between the small molecules and the a 1 /2 pocket and requires further exploration.
  • 0161 interacts with the molecules through either suifur-n or sulfuralkyl interactions.
  • Compounds 1 , 4, 5, 17, and 18 interact with C161 through an edge-on sulfu r-alkyl interaction. The weak sulf ur-aiky! interaction could cause the lowered activity of these molecules.
  • Compounds 2, 7, 9, and 19, are the most potent and efficient small molecules reported, and are predicted to interact with C161 through an edge-on n-sulfur interactions (FIGS. 2C-F).
  • ab- initio calculations have been used to determine the ideal geometry for cysteine- pi interactions, identifying abundance or strong edge-on cysteine-ir interactions.
  • the 20S proteasome activity of the compounds was assessed by utilizing the standard fluorogenic 7-amino- methyicoumarin (AMC) conjugated small peptide substrates that correspond to each of the catalytic sites in the 20S proteasome: chymotryptic-like site (Suc- LLVY-AMC), caspase-like site (Z-LLE-AMC), and trypsin-like site (Boc-LRR- AMC).
  • AMC 7-amino- methyicoumarin
  • the 20S proteasome activity of the small molecules was evaluated at varying concentrations to determine the concentration at which the rate of proteolysis was doubled (i.e. the concentration needed to induce 200% activity) compared to the vehicle control (hereafter named as AC 2 oo). Concentrations ranging from 1.25 pM to 80 pM of each of compound were added to wells that contained 0.5 nM of purified human proteasome.
  • the overall enhancement of the rate of proteolysis of the 20S proteasome by a small molecule was first evaluated by adding a combination of all three peptide substrates to the treated sample.
  • the combination of all three substrates represents a more accurate measurement of proteolytic activity of the proteasome because the catalytic sites housed in the p ring of the 20S proteasome communicate through allosteric interactions. For example, when a protein substrate encounters the chymotryptic-like site, a conformational change will occur activating the caspase-like site . 6i
  • the individual contribution of each of the three catalytic sites was subsequently evaluated by adding only the corresponding peptide probes to gain insight into the contribution of each site on the overall enhanced proteolytic activity.
  • Table 1 shows increase in proteolytic degradation of Suc-LLVY- AMC chymo-tryptic-like probe (CT-L), Z-LLE-AMC caspase-like probe (Casp-L), and Boc-LRR-AMC trypsin-like probe (T-L), combined and each of the individual three substrate probes, by purified human 20S proteasome treated with compounds 1-11 and 15-19.
  • AC200 represents the concentration needed to double (e.g., 200%) the rate of substrate degradation compared to vehicle control.
  • Max fold is the maximum fold rate increase compared to vehicle control.
  • GPZ significantly enhanced 20S mediated proteolysis.
  • the unsubstituted benzyl derivative (1) enhanced 20S proteasome mediated proteolysis 2-fold (i.e. 200% increase over vehicle control) at a relatively low AC200 of 1 .5 pM.
  • Compound 1 's overall rate of proteolysis appeared to be due to the enhanced activity at the chymotryptic-like and trypsin-like sites.
  • the t-butyl (3), the acetate (6), and alcohol (8) benzyl derivates are ali deemed inactive as they do not reach a 200% increase in proteasome activity at the concentrations tested.
  • Analog 4 has an AC200 of 1 .5 pM, which is very similar to compound 2 (1 .4 pM).
  • compound 4 is less than half as efficient as compound 2 (maximum fold of 4). This finding suggests that either the carbonyl group aids activation and/or it may impact the interactions of the benzyl ring.
  • the meta derivative of compound 2 (5) has a higher AC200 (2.4 pM) but a lower maximum fold increase of 6 (i.e. 600% increase over vehicle control).
  • compound 7 had a similar maximum fold increase of 8 (i.e. 800% increase over vehicle control) and had a relatively low AC200 (1 .1 pM). The transformation of this nitro group into the primary amine does not affect the overall 20S proteasome activation but did raise the AC200 (3.6 pM).
  • the addition of two aryl groups onto the nitrogen enhances 20S proteasome activation.
  • Compound 19 displays a maximum 1 1 -fold (i.e. 1 100% increase over vehicle control) enhancement of the proteolytic activity of the 20S proteasome, with potent AC200 values and fold enhancements of each of the three catalytic sites.
  • Compound 19 activated the trypsin-like site with an AC200 of 0.3 pM, (6-fold maximum enhancement), the chymotryptic-like site with an AC200 of 0.7 pM, (9.4-fold maximum enhancement), and the caspase-like site with an AC200 of 1.8 pM, (9.4-fold maximum enhancement).
  • IDP degradation The ability of our small molecules SOS proteasome activators to degrade pathologically relevant IDPs was evaluated in vitro and in cells.
  • the efficacy of compound 19 on 20S-mediated degradation of a-synuclein was evaluated in vitro using compound 2 and TCH- 165, a previously reported 20S proteasome enhancer, as a positive control and the inactive analogue (8) as a negative control.
  • Purified 20S proteasome was incubated at 37° C with either compound 2, 8, 19 (concentrations 0.1 pM to 5 pM) or TCH-165 (5 pM) for 15 minutes.
  • CeliiOar efficacy The A53T mutation of a-synuclein has been linked to early on-set familial Parkinson's disease and appears to oligomerize faster than the wild-type protein. We evaluated compound 19 ! s ability to prevent the accumulation of the A53T mutant a-synuciein in cells. Hek-293T cells were transiently transfected with an inducible Tet-One A53T mutant a-synuclein. The cells were treated with 100 ng/mL of doxycycline to induce the production of the A53T mutant.
  • the cells were treated with compound 19 (3 pM, 5 pM, and 10 pM), the control compounds TCH-165, compound 2, compound 8 (10 pM each), and proteasome inhibitor bortezomib (BTZ, 5pM), for 10 hours.
  • Bortezomib (BTZ) a known proteasome inhibitor, was used a negative control and TCH-165 was once again used as a positive control and was observed to decrease the concentration of accumulated A53T a-synuclein by 40%.
  • Compound 2 displayed a reduction of 28% of the A53T mutant a-synuclein, while compound 8 had no decrease in the A53T mutant.
  • Compound 19 was able to reduce the concentration of the A53T mutant a-synuciein significantly at its lowest concentration, 3 pM and a dose dependent enhanced degradation was observed. At the highest concentration of compounds 19, 10 pM, the A53T a-synuclein was decreased by 58%.
  • the potency and efficiency displayed by compound 19 towards the 20S proteasome in previous experiments does translate io tne degradation or A53T mutant a- synuclein in HEK293T cells.
  • 5-(2-Chloro-10W ⁇ phenothiazin ⁇ 10-yl)pentanamide (11). 5-(2- chloro-10H-phenothiazin-10-yl)pentanenitrile (10) was dissolved in 7 mL concentrated sulfuric acid and stirred for 2.5 hours in a round bottom flask. The solution was then poured into 20 mL ice-water mixture and basified to pH 10 with concentrated ammonium hydroxide (caution: add slow and keep solution cold). Mixture was then extracted with EtOAc (3x 100 mL), washed with brine (1 x 100 mL), dried over sodium sulfate, and concentrated in vacuo to give the title compound (95%).
  • General acylation procedure provided a white solid (0.380 g, 86%).
  • reagent, blocking grade milk, and precast sodium dodecyl sulfate gels were from Bio-Rad (Hercules, CA).
  • the recombinant wild type a-synuclein was obtained from Abeam (Cambridge, MA).
  • Rabbit polyclonal anti-a-synuclein, mouse monoclonal anti-a- synuclein and goat anti-rabbit HRP-linked antibody were purchased from Santa Cruz Biotechnologies (Dalias, TX).
  • the anti-mouse HRP-linked antibody was purchased from Cell Signaling Technology (Danvers, MA). Unless otherwise noted, chemicals were purchased from commercial suppliers and used without further purification.
  • the 96 well plate is then placed into a plate reader (SpectraMax M5e spectrometer) and the plate reader will take a fluorescent reading every 5 minutes for an hour at 37 e C.
  • the enzymatic activity of the 20S proteasome is quantified using the fluorescent output at 380-460 nm, which is converted to max fold increase over the untreated sample.
  • the activity of the individual catalytic assays is identical to the assay that assesses the overall activity of the 20S proteasome except only one small peptide substrate is added.
  • Digestion of purified a-synuclein Degradation assays were carried out in a 50 pL reaction volume of 50 nM Tris-HCI and 100 nM NaCI buffer at a pH of 7.8, 0.5 pM of purified a-synuclein, and 7.5 nM purified human 20S proteasome.
  • the 20S proteasome was first diluted to 8.56 nM in the Tris-HCI buffer and 1 pL of the test compounds or DMSO was added. This mixture was incubated for 20 minutes at 37 °C. After this incubation, 5 pL of a 5 pM stock of a-synuclein was added.
  • the degradation mixture was incubated at 37 °C for 5 hours. The reaction was stopped with addition of concentrated SDS loading buffer and booed for 10 minutes. After the samples were boned, they were resolved on a 4-20% Tris-glycine SDS-PAGE gel and visualized using silver staining.
  • PCR reagent system 12.5 mL of the CloneAmp HiFi PCR Premix was added to 5-7.5 pmol of primer A (the amount will be dependent on the dilution of the primers) (ttttataggcgccctggttt), primer B (tgtatttagaaaaataaacaaata), and 100 ng of A53T template were added and sterilized deionized water was added to bring the mixture volume up to 25 mL.
  • the mixture was then put into a thermal cycler and the following cycle was carried out: 96 °C for 3 minutes, then 30 cycles of 96 °C for 10 seconds, 64 °C for 10 seconds, and 72 °C for 66 seconds, and one cycle of 72 °C for 10 minutes.
  • A53T a-synucleln In a 6 well plate, Hek293T cells were grown to 80% confluency and then transfected using Xfect biopolymer transfection system with the Tet-One A53T a-synuclein plasmid. 24 hours post transfection, 100 ng/mL of doxycycline was added to induce A53T a- synuclein expression. After 24 hours of protein induction, media was removed that contained the doxycycline and was washed with PBS. Media with the desired drug concentration or DMSO was added and treated for 10 hours.
  • the cells were scraped and the pelleted (300g for 5 minutes). The supernatant was taken off and the cel! pellet was washed with Ice cold PBS and then lysed with RIPA buffer with added protease inhibitors. The cell lysate was incubated for 20 minutes on ice. The lysate was centrifuged for 15 minutes at 500 g and then the supernatant was collected. Concentrated SDS loading buffer was added and the samples were boiled for 10 minutes.
  • the samples were then resolved on a 4-20% Tris-glycine SDS-PAGE gel and immunoblotted with mouse monoclonal anti a- synuclein IgG (1 :2000) and anti-mouse HRP-linked IgG (1 :2000). Blots were developed with ECL Western reagent and imaged with an Azure Biosystems 300Q imager.
  • Embodiment 1 relates to a compound of the formula (Ip
  • FT is hydrogen, alkyl, cycloalkyl, aryl, heterocyclyl or heteroaryl;
  • R 2 is hydrogen, alkyl, cycloalkyl, aryl, heterocyclyl or heteroaryl;
  • R 3 is aryl or heteroaryl
  • X 1 is N or CR 5 , wherein R 5 is absent, hydrogen, alkyl, heterocyclyl or aryl;
  • X 2 is alkyl or alkenyl
  • X 3 is alkyl or alkenyl; g is 0 or 1 ; and t is 0 or 1 ; provided that g and t are not simultaneously 0. In some examples, g is 0 and t is
  • g is 1 and t is 0.
  • Embodiment relates to the compound of Embodiment 1 , wherein the compound of the formula (I) is a compound of the formula (la) : or a pharmaceutically acceptable salt, polymorph, prodrug, solvate or clathrate thereof, wherein:
  • R ! is hydrogen, alkyl, cycloalkyi, aryl, heterocyclyl or heteroaryl;
  • R 2 is hydrogen, alkyl, cycloalkyi, aryl, heterocyclyl or heteroaryl;
  • R 3 is aryl or heteroaryl
  • X 1 is N or CR 5 , wherein R 5 is absent, hydrogen, alkyl, heterocyclyl or aryl;
  • X 2 is alkyl or alkenyl
  • X 3 is alkyl or alkenyl; g is 0 or 1 ; and t is 0 or 1 ; provided that g and t are not simultaneously 0; R 4 is alkyl, cycloalkyl, aryl, heteroaryl, halo, amino, OR' , wherein R' is hydrogen, alkyl, cycloalkyl, aryl or arylalkyl, S(O)x, wherein x is 0, 1 or 2, acyl, amido or heterocyclyl;
  • R 6 is aikyl, cycloalkyl, aryl, heteroaryl, halo, amino, OR 7 , wherein R 7 is hydrogen, aikyl, cycloalkyl, aryl or arylalkyl, S(O) X , wherein x is Q, 1 or 2, acyl, amido or heterocyclyl; p is 0, 1 , 2, 3 or 4; and s is 0, 1 , 2, 3 or 4.
  • Embodiment 3 relates to the compound of Embodiment 1 , wherein the compound of formula (!) Is a compound of the formula (ib) or (ic):
  • Embodiment 4 relates to the compound of Embodiment 1 , wherein the compound of formula (I) is a compound of the formula (Id) or (ie):
  • Embodiment 5 relates to the compound of Embodiment 1 , wherein the compound of formula (! is a compound of the formula (If): or a pharmaceutically acceptable salt, polymorph, prodrug, solvate or clathrate thereof, wherein:
  • R 3 is aryl or heteroaryl
  • X 1 is N or CR 5 , wherein R 5 is absent, hydrogen, alkyl, heterocyclyi or aryl;
  • X 2 is alkyl or alkenyl
  • X 3 is alkyl or alkenyl; g is 0 or 1 ; and t is 0 or 1 ; provided that g and t are not simultaneously 0.
  • Embodiment 6 relates to the compound of Embodiment 5, wherein g is 0 and t is 1 .
  • Embodiment 7 relates to the compound of Embodiment 5, wherein g is 1 and t is 0
  • Embodiment 8 relates to the compound of Embodiment 1 , wherein the compound of the formula (I) is a compound of the formula (Ig): or a pharmaceutically acceptable salt, polymorph, prodrug, solvate or clathrate thereof, wherein:
  • X 1 is N or CR 5 , wherein R 5 is absent, hydrogen, alkyl, heterocyclyi or aryl;
  • X 2 is alkyl or alkenyl
  • X 3 is alkyl or alkenyl; g is 0 or 1 ; and t is 0 or 1 ; provided that g and t are not simultaneously 0
  • Embodiment 9 relates to the compound of Embodiment 8, wherein g is 0 and t is 1 .
  • Embodiment 10 relates to the compound of Embodiment 8, wherein g is 1 and t is 0
  • Embodiment 11 relates to the compound of Embodiment 1 , wherein the compound of formula (I) is a compound of the formula (Ih) or (li):
  • Embodiment 12 relates to the compound of Embodiment 1 , wherein the compound of the formula (I) is a compound of the formula (ii) or (Ik): or a pharmaceutically acceptable salt, polymorph, prodrug, solvate or clathrate thereof, wherein: n is 0, 1 or 2.
  • Embodiment 13 relates to the compound of Embodiment 1 , wherein the compound of the formula (I) is a compound of the formula (II):
  • n 0, 1 or 2;
  • Y is S(O) X> wherein x is 0, 1 or 2, O, CH2, or Y is N-R", wherein R 1 ! is a carbon with at least one halo, alkyl, aryl, acyl or heterocyclyi;
  • R 7 , R 8 , R s , and R 10 are each independently halo, a carbon with at least one halo, alkyl, aryl, acyl or heterocyclyi; p is 0, 1 , 2, 3 or 4; and s is 0, 1 , 2, 3 or 4.
  • Embodiment 14 relates to the compound of Embodiment 1 , wherein the compound of the formula (I) is a compound of the formula: pharmaceutically acceptable salts, polymorphs, prodrugs, solvates or clathrates thereof.
  • Embodiment 15 relates to a compound of the formula (III): or a pharmaceutically acceptable salt, polymorph, prodrug, solvate or clathrate thereof, wherein: n is 0, 1 or 2;
  • R 7 and R B are each independently halo, a carbon with at least one halo, alkyl, aryl, acyl or heterocyclyl;
  • R i3 is a heterocyclyl group of the formula: wherein W is N or OR 14 ; X is N or OR 14 ; Y is N or OR 14 ; and Z is N or C-R !4 ; wherein R i4 is hydrogen, an electron withdrawing group, alkyl, cycloalkyl, aryl, heteroaryl, acyl, amido or heterocyclyl, wherein each aryl or heteroaryl is optionally substituted with halo, amino, OR 7 , wherein R 7 is hydrogen, alkyi, cycloalkyl, aryl or arylalkyl, S(O) X , wherein x is 0, 1 or 2, acyl, amido or heterocyclyl;
  • R 4 is alkyi, cycloalkyl, aryl, heteroaryl, halo, amino, OR'', wherein R z is hydrogen, alkyl, cycloalkyl, aryl or arylalkyl, S(O) X , wherein x is 0, 1 or 2, acyl, amido or heterocyclyl; and p is 0, 1 , 2, 3 or 4; wherein the dashed line can represent a double bond; A is S(O) X , wherein x is 0, 1 or 2; O; C(R' 4 )K, wherein each R 14 is independently hydrogen, an electron withdrawing group, alkyl, cycloalkyl, aryl, heteroaryl, acyl, amido or heterocyclyl, wherein each aryl or heteroaryl is optionally substituted with halo, amino, OR 7 , wherein R 7 is hydrogen, alkyi, cycloalkyl, aryl or arylalkyl, S(O)
  • Embodiment 16 relates to the compound of Embodiment 15, wherein the compounds of the formula (III) are compounds of the formulae:
  • Embodiment 17 relates to the compound of Embodiment 15, wherein the compounds of the formula (III) are compounds of the formulae: pharmaceuucally acceptable salt, polymorph, prodrug, solvate or clathrate thereof.
  • Embodiment 18 relates to the compound of Embodiment 15, wherein the compounds of the formula (III) are compounds of the formulae: pharmaceutically acceptable salt, polymorph, prodrug, solvate or clathrate thereof.
  • Embodiment 19 relates to the compound of Embodiment 15, wherein the compounds of the formula (III) are compounds of the formulae:
  • Embodiment 20 relates to the compound of Embodiment 15, wherein the compounds of the formula (III) are compounds of the formulae: or a pharmaceutically acceptable salt, polymorph, prodrug, solvate or clathrate thereof
  • Embodiment 21 relates to a compound of the formula (IV): or a pharmaceutically acceptable salt, polymorph, prodrug, solvate or clathrate thereof, wherein: n is 0, 1 or 2; each G is independently alkyl or 0(0);
  • X 5 is N or CR S , wherein R s is hydrogen, alkyl, heterocyciyl or aryl;
  • R 7 and R 8 are each independently halo, a carbon with at least one halo (e.g., one to three halo, such as CHF 2 , CCF 3 , CCh), alkyl, aryl, acyl or heterocyciyl; and R 13 is a heterocyciyl group of the formula: wherein W is N or C-R 14 ; X is N or C-R 14 ; Y is N or C-R 14 ; and Z is N or C-R’ 4 ; wherein R' 4 is hydrogen, an electron withdrawing group, alkyl, cycloalkyl, aryl, heteroaryl, acyl, amido or heterocyciyl, wherein each aryl or heteroaryl is optionally substituted with halo, amino, OR 7 , wherein R 7 is hydrogen, alkyl, cycioaikyl, aryl or arylalkyl, S(O) X> wherein x is 0,
  • R 4 is alkyl, cycloalky I, aryl, heteroaryl, halo, amino, OR 7 , wherein R 7 is hydrogen, alkyl, cycloalkyl, aryl or arylalkyl, S(O) X , wherein x is 0, 1 or 2, acyl, amido or heterocyciyl; and p is 0, 1 , 2, 3 or 4; wherein A is S(O) X , wherein x is 0, 1 or 2; O; C-R 14 , wherein R 14 is hydrogen, alkyl, cycloalkyi, aryl, heteroaryl, acyl, amido or heterocyclyl, wherein each aryl or heteroaryl is optionally substituted with halo, amino, OR 7 , wherein R 7 is hydrogen, alkyl, cycloalkyi, aryl or arylalkyl, S(O) X , wherein x is 0, 1 or 2, acyl, amido or hetero
  • B is C-R 14 , wherein R 14 is hydrogen, an electron withdrawing group, alkyl, cycloalkyi, aryl, heteroaryl, acyl, amido or heterocyclyl, wherein each aryl or heteroaryl is optionally substituted with halo, amino, OR 7 , wherein R 7 is hydrogen, alkyl, cycloalkyi, aryi or arylalkyl, S(O) X , wherein x is 0, 1 or 2, acyl, amido or heterocyclyl; or B is N;
  • Embodiment 22 relates to the compound of Embodiment 21 , wherein the compounds of the formula (IV) are compounds of the formulae:
  • Embodiment 23 relates to the compound of Embodiment 21 , wherein the compounds of the formula (IV) are compounds of the formulae:
  • polymorph, prodrug, solvate or clathrate thereof polymorph, prodrug, solvate or clathrate thereof.
  • Embodiment 24 relates to the compound of Embodiment 21 , wherein the compounds of the formula (IV) are compounds of the formulae: , polymorph, prodrug, solvate or clathrate thereof.
  • Embodiment 25 relates to the compound of Embodiment 21 , wherein the compounds of the formula (IV) are compounds of the formulae: pharmaceutically acceptable salt, polymorph, prodrug, solvate or clathrate thereof.
  • Embodiment 26 relates to the compound of Embodiment 21 , wherein the compounds of the formula (IV) are compounds of the formulae:
  • Embodiment 27 relates to a compound of the formula (V): or a pharmaceutically acceptable salt, polymorph, prodrug, solvate or clathrate thereof, wherein: n is 0, 1 or 2; each G is independently alkyl or C(O);
  • R 7 and R 8 are each independently halo, a carbon with at least one halo, alkyl, aryl, acyl or heterocyclyl; or R 7 and R 8 , together with the nitrogen atom to which they are attached, can form a heterocyclyl; and
  • R 13 is a heterocyclyl group of the formula: wherein W is N or C-R 14 ; X is N or C-R 14 ; Y is N or C-R 14 ; and Z is N or C-R 14 ; wherein R i4 is hydrogen, an eiectron withdrawing group, alkyl, cycioaikyl, aryl, heteroaryl, acyl, amido or heterocyclyl, wherein each aryl or heteroaryl is optionally substituted with halo, amino, OR 7 , wherein R 7 is hydrogen, alkyl, cycloalkyl, aryl or arylalkyl, S(O) Xs wherein x is 0, 1 or 2, acyl, amido or heterocyclyl;
  • R 4 is alkyl, cycloalkyl, aryl, heteroaryl, halo, amino, OR 7 , wherein R 7 is hydrogen, alkyl, cycloalkyl, aryl or arylalkyl, S(O) X , wherein x is Q, 1 or 2, acyl, amido or heterocyclyl; and p is 0, 1 , 2, 3 or 4; wherein A is S(O) X , wherein x is Q, 1 or 2; O; C-R 14 , wherein R 14 is hydrogen, alkyl, cycloalkyl, aryl, heteroaryl, acyl, amido or heterocyclyl, wherein each aryl or heteroaryl is optionally substituted with halo, amino, OR 7 , wherein R 7 is hydrogen, alkyl, cycioaikyl, aryl or arylaikyl, S(O) X , wherein x is 0, 1 or 2, acyl, amid
  • B is C-R 14 , wherein R 14 is hydrogen, an eiectron withdrawing group, alkyl, cycioaikyl, aryi, heteroaryl, acyl, amido or heterocyclyl, wherein each aryl or heteroaryl is optionally substituted with halo, amino, OR 7 , wherein R 7 is hydrogen, alkyl, cycioaikyl, aryl or arylaikyl, S(O) X , wherein x is 0, 1 or 2, acyl, amido or heterocyclyl; or B is N;
  • Embodiment 28 relates to the compound of Embodiment 27, wherein the compounds of the formula (V) are compounds of the formulae: pharmaceutically acceptable salt, polymorph, prodrug, solvate or clathrate thereof.
  • Embodiment 29 relates to the compound of Embodiment 27, wherein the compounds of the formula (V) are compounds of the formulae:
  • Embodiment 30 relates to the compound of Embodiment 27, wherein the compounds of the formula (V) are compounds of the formulae:
  • Embodiment 31 relates to the compound of Embodiment 27, wherein the compounds of the formula (V) are compounds of the formulae:
  • Embodiment 32 relates to the compound of Embodiment 27, wherein the compounds of the formula (V) are compounds of the formulae:
  • Embodiment 33 relates to a compound of the formula (VI): or a pharmaceutically acceptable salt, polymorph, prodrug, solvate or clathrate thereof, wherein: n Is 0, 1 or 2; each G Is Independently alkyl or 0(0); and
  • R 7 and R 8 are each independently halo, a carbon with at least one halo, aikyl, aryl, acyl or heterocyclyl;
  • R iS is alkyl, haloalkyl, cycloalkyl, aryl, heteroaryl, halo, amino, OR 7 , wherein R 7 is hydrogen, alkyl, cycloalkyl, aryl or arylalkyi, S(O) X> wherein x is 0, 1 or 2, acyl, amido or heterocyclyl; and p is 0, 1 , 2, 3 or 4; wherein X 7 is N or C-R 18 ; wherein R 18 is hydrogen, an electron withdrawing group, alkyl, cycloalkyl, aryl, heteroaryl, acyl, amido or heterocyclyl, wherein each aryl or heteroaryl is optionally substituted with halo, amino, OR 7 , wherein R 7 is hydrogen, aikyl, cycloalkyl, aryl or arylalkyi, S(O) X , wherein x is 0, 1 or 2, acyl, amido or heterocyclyl
  • R 16 is alkyl, haloalkyl, cycioalkyl, aryl, heteroaryl, halo, amino, OR'', wherein R'' is hydrogen, alkyl, cycloalkyi, aryl or arylalkyi, S(O) X , wherein x is 0, 1 or 2, acyl, amido or heterocyclyl; and p is 0, 1 , 2, 3 or 4;
  • Y is N or C-R 14 ; and Z is N or C-R 14 ; wherein R 14 is hydrogen, an electron withdrawing group, alkyl, cycloalkyi, aryl, heteroaryl, acyl, amido or heterocyclyl, wherein each aryl or heteroaryl is optionally substituted with halo, amino, OR 7 , wherein R 7 is hydrogen, aikyl, cycloalkyl, aryl or arylalkyi, S(O) X , wherein x is 0, 1 or 2, acyl, amido or heterocyclyl; wherein X 8 is NR’ 9 , wherein R 19 is H, alkyl or aryl or X 8 is C(R 18 )2; wherein each R’ 8 is independently hydrogen, an electron withdrawing group, aikyl, cycloalkyl, aryl, heteroaryl, acyl, amido or heterocyclyl, wherein each aryl or heteroaryl is optionally substitute
  • R' 6 is alkyl, haloalky I, cycloalkyl, aryl, heteroaryl, halo, amino, OR 7 , wherein R 7 is hydrogen, alkyl, cycloalkyl, aryl or arylalkyl, S(O) X , wherein x is 0, 1 or 2, acyl, amido or heterocyclyl; and p is 0, 1 , 2, 3 or 4;
  • Embodiment 34 relates to the compound of Embodiment 33, wherein the compound is a compound of the formula:
  • Embodiment 35 relates to a pharmaceutical composition comprising one or more compounds of any preceding claim and one or more pharmaceutically acceptable excipients.
  • Embodiment 36 relates to a method for treating a neurodegenerative disease comprising administering a therapeutically effective amount of chlorpromazine, at least one compound of Embodiments 1 -34 or a pharmaceutical composition of Embodiment 35 to a subject in need thereof.
  • Embodiment 37 relates to the method of Embodiment 36, wherein the neurodegenerative disease is at least one of Parkinson’s disease, Alzheimer’s disease, Huntington's disease, and ALS.
  • Embodiment 38 relates to a method for reducing, substantially eliminating or eliminating dysregulation of proteostasis comprising administering a therapeutically effective amount of chlorpromazine, at least one compound of Embodiments 1 -34 or a pharmaceutical composition of Embodiment 35 to a subject in need thereof.
  • Embodiment 39 relates to a method for reducing, substantially eliminating or eliminating the accumulation of intrinsically disordered proteins comprising administering a therapeutically effective amount of chlorpromazine, at least one compound of Embodiments 1 -34 or a pharmaceutical composition of Embodiment 35 to a subject in need thereof.

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Plural Heterocyclic Compounds (AREA)
PCT/US2021/045448 2020-08-11 2021-08-10 Proteasome enhancers and uses thereof Ceased WO2022035904A1 (en)

Priority Applications (7)

Application Number Priority Date Filing Date Title
PCT/US2021/045448 WO2022035904A1 (en) 2020-08-11 2021-08-10 Proteasome enhancers and uses thereof
AU2021324687A AU2021324687A1 (en) 2020-08-11 2021-08-10 Proteasome enhancers and uses thereof
JP2023509838A JP2023538325A (ja) 2020-08-11 2021-08-10 プロテアソームエンハンサー及びその使用
EP21856603.2A EP4196464A4 (en) 2020-08-11 2021-08-10 PROTEASOMAL INHIBITORS AND THEIR USES
US18/041,193 US20240043394A1 (en) 2020-08-11 2021-08-10 Proteasome enhancers and uses thereof
MX2023001761A MX2023001761A (es) 2020-08-11 2021-08-10 Potenciadores de proteasoma y usos de los mismos.
CA3191312A CA3191312A1 (en) 2020-08-11 2021-08-10 Proteasome enhancers and uses thereof

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202063064262P 2020-08-11 2020-08-11
US63/064,262 2020-08-11
PCT/US2021/045448 WO2022035904A1 (en) 2020-08-11 2021-08-10 Proteasome enhancers and uses thereof

Publications (1)

Publication Number Publication Date
WO2022035904A1 true WO2022035904A1 (en) 2022-02-17

Family

ID=83103414

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2021/045448 Ceased WO2022035904A1 (en) 2020-08-11 2021-08-10 Proteasome enhancers and uses thereof

Country Status (7)

Country Link
US (1) US20240043394A1 (cg-RX-API-DMAC7.html)
EP (1) EP4196464A4 (cg-RX-API-DMAC7.html)
JP (1) JP2023538325A (cg-RX-API-DMAC7.html)
AU (1) AU2021324687A1 (cg-RX-API-DMAC7.html)
CA (1) CA3191312A1 (cg-RX-API-DMAC7.html)
MX (1) MX2023001761A (cg-RX-API-DMAC7.html)
WO (1) WO2022035904A1 (cg-RX-API-DMAC7.html)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2025124250A (ja) * 2024-02-14 2025-08-26 株式会社ジェイテクト 転舵制御装置

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1469772A (en) * 1973-06-21 1977-04-06 Boots Co Ltd Fungicidal imidazole derivatives
DE4430091A1 (de) * 1994-08-25 1996-02-29 Bayer Ag Verwendung von N-substituierten Phenothiazinen
SI0999826T1 (en) * 1997-07-29 2004-12-31 Pharmacia & Upjohn Company Self-emulsifying formulation for lipophilic compounds
EP1268477B1 (en) * 2000-03-15 2010-04-21 Sanofi-Aventis Deutschland GmbH Substituted beta-carbolines with ikb-kinase inhibiting activity
MX2013000391A (es) * 2010-07-12 2013-03-08 Hoffmann La Roche 1-hidroxiimino-3-fenil-propanos.
JP6490464B2 (ja) * 2014-03-26 2019-03-27 三井化学株式会社 遷移金属化合物、オレフィン重合用触媒およびオレフィン系重合体の製造方法
CN107021938A (zh) * 2017-05-26 2017-08-08 陕西科技大学 一种1‑吩噻嗪基‑3‑芳基‑3‑氰基亚甲基‑1‑丙酮及其制备方法
CN107216323A (zh) * 2017-05-26 2017-09-29 陕西科技大学 一种1‑吩噻嗪基‑3‑芳基‑3‑(2,4,6‑嘧啶三酮基)‑1‑丙酮及其制备方法
WO2019084157A1 (en) * 2017-10-24 2019-05-02 Yumanity Therapeutics, Inc. COMPOUNDS AND USES THEREOF
WO2019156991A1 (en) * 2018-02-06 2019-08-15 The Regents Of The University Of California Methods of inhibiting formation of alpha synuclein aggregates

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
DATABASE PubChem Compound 31 May 2019 (2019-05-31), ANONYMOUS : "AKOS004114654", XP055910473, retrieved from PubChem Database accession no. 108661858 *
DATABASE Pubchem Compound ANONYMOUS : "Propiophenone, analytical standard", XP055910445, retrieved from Pubchem *
DOMÍNGUEZ-PRIETO MARTA, VELASCO ANA, TABERNERO ARANTXA, MEDINA JOSÉ M.: "Endocytosis and Transcytosis of Amyloid-β Peptides by Astrocytes: A Possible Mechanism for Amyloid-β Clearance in Alzheimer’s Disease", JOURNAL OF ALZHEIMER`S DISEASE, IOS PRESS, NL, vol. 65, no. 4, 25 September 2018 (2018-09-25), NL , pages 1109 - 1124, XP055910439, ISSN: 1387-2877, DOI: 10.3233/JAD-180332 *

Also Published As

Publication number Publication date
EP4196464A1 (en) 2023-06-21
CA3191312A1 (en) 2022-02-17
US20240043394A1 (en) 2024-02-08
JP2023538325A (ja) 2023-09-07
AU2021324687A1 (en) 2023-04-20
EP4196464A4 (en) 2024-12-25
MX2023001761A (es) 2023-04-11

Similar Documents

Publication Publication Date Title
US20230295116A1 (en) Proteasome enhancers and uses thereof
US11155561B2 (en) Substituted glutarimides as Btk inhibitors
US10954258B2 (en) STAT3 dimerization inhibitors
Peng et al. RETRACTED ARTICLE: Discovery of novel benzohydroxamate-based histone deacetylase 6 (HDAC6) inhibitors with the ability to potentiate anti-PD-L1 immunotherapy in melanoma
CA3142713A1 (en) Compounds that degrade kinases and uses thereof
AU2021324687A1 (en) Proteasome enhancers and uses thereof
US12084421B2 (en) Quinoline-based proteasome inhibitors and uses thereof
US20250179031A1 (en) Proteasome enhancers and uses thereof
KR101711731B1 (ko) 패혈증 예방 또는 치료용 약학적 조성물
US12060337B2 (en) Substituted dibenzo[b, f]azepines as proteasome activators
US20250289810A1 (en) Compounds As NLRP3 Inflammasome Inhibitors And Their Use As Medicaments
WO2022035902A1 (en) Proteasome enhancers and uses thereof
US11230550B2 (en) Macrocyclic HIV-1 protease inhibitors and uses thereof
Goyal et al. Design, Synthesis, In Vitro Hydrolysis and Biological Evaluation of Antioxidant-Conjugated Mutual Prodrugs of Naproxen
EP4676475A1 (en) Hiv-1p rotease inhibitors and uses thereof
Ni et al. Discovery of γ-Tetrahydrocarboline Derivatives as Plasmodium falciparum Histone Deacetylase Inhibitors for Treatment of Malaria
Selim et al. Ibuprofen amino acid derivatives: synthesis, docking and biological studies
PL243517B1 (pl) Pochodne (benzyloksy)benzenu nadające się do stosowania w immunoterapii nowotworów oraz zawierająca je kompozycja farmaceutyczna

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 21856603

Country of ref document: EP

Kind code of ref document: A1

ENP Entry into the national phase

Ref document number: 3191312

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 18041193

Country of ref document: US

ENP Entry into the national phase

Ref document number: 2023509838

Country of ref document: JP

Kind code of ref document: A

NENP Non-entry into the national phase

Ref country code: DE

ENP Entry into the national phase

Ref document number: 2021856603

Country of ref document: EP

Effective date: 20230313

ENP Entry into the national phase

Ref document number: 2021324687

Country of ref document: AU

Date of ref document: 20210810

Kind code of ref document: A